WO2001011951A1 - Mouse having human cytochrome p450 transferred therein - Google Patents
Mouse having human cytochrome p450 transferred therein Download PDFInfo
- Publication number
- WO2001011951A1 WO2001011951A1 PCT/JP2000/005424 JP0005424W WO0111951A1 WO 2001011951 A1 WO2001011951 A1 WO 2001011951A1 JP 0005424 W JP0005424 W JP 0005424W WO 0111951 A1 WO0111951 A1 WO 0111951A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mouse
- gene
- human
- cells
- cyp3a
- Prior art date
Links
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 title claims description 43
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title claims description 17
- 210000004027 cell Anatomy 0.000 claims abstract description 360
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 201
- 239000012634 fragment Substances 0.000 claims abstract description 131
- 210000003917 human chromosome Anatomy 0.000 claims abstract description 130
- 101150053185 P450 gene Proteins 0.000 claims abstract description 124
- 210000000349 chromosome Anatomy 0.000 claims abstract description 107
- 239000013598 vector Substances 0.000 claims abstract description 102
- 238000000034 method Methods 0.000 claims abstract description 76
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims abstract description 71
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims abstract description 65
- 210000001519 tissue Anatomy 0.000 claims abstract description 31
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 303
- 241000699670 Mus sp. Species 0.000 claims description 85
- 239000000523 sample Substances 0.000 claims description 60
- 230000014509 gene expression Effects 0.000 claims description 56
- 108091008053 gene clusters Proteins 0.000 claims description 38
- 230000008685 targeting Effects 0.000 claims description 38
- 238000004519 manufacturing process Methods 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 31
- 230000006798 recombination Effects 0.000 claims description 27
- 238000005215 recombination Methods 0.000 claims description 27
- 238000011813 knockout mouse model Methods 0.000 claims description 25
- 238000012216 screening Methods 0.000 claims description 25
- 238000009396 hybridization Methods 0.000 claims description 23
- 230000002950 deficient Effects 0.000 claims description 21
- 238000010367 cloning Methods 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 238000012258 culturing Methods 0.000 claims description 18
- 239000002299 complementary DNA Substances 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- 230000000717 retained effect Effects 0.000 claims description 11
- 230000004060 metabolic process Effects 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 7
- 238000007500 overflow downdraw method Methods 0.000 claims description 6
- 230000002759 chromosomal effect Effects 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 230000000144 pharmacologic effect Effects 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 101710200251 Recombinase cre Proteins 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 24
- 210000000813 small intestine Anatomy 0.000 abstract description 9
- 101000745711 Homo sapiens Cytochrome P450 3A4 Proteins 0.000 abstract description 8
- 210000002950 fibroblast Anatomy 0.000 abstract description 4
- 238000010363 gene targeting Methods 0.000 abstract description 4
- 210000001671 embryonic stem cell Anatomy 0.000 abstract description 3
- 108700026220 vif Genes Proteins 0.000 abstract description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 134
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 100
- 108020004414 DNA Proteins 0.000 description 99
- 239000013612 plasmid Substances 0.000 description 84
- 108091008146 restriction endonucleases Proteins 0.000 description 74
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 63
- 239000002609 medium Substances 0.000 description 57
- 239000000243 solution Substances 0.000 description 36
- 230000000692 anti-sense effect Effects 0.000 description 34
- 239000000047 product Substances 0.000 description 31
- 210000002257 embryonic structure Anatomy 0.000 description 28
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 25
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 24
- 239000000872 buffer Substances 0.000 description 24
- 239000012091 fetal bovine serum Substances 0.000 description 24
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 23
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 23
- 239000005090 green fluorescent protein Substances 0.000 description 23
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 22
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 22
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 22
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 22
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 22
- 230000006801 homologous recombination Effects 0.000 description 22
- 238000002744 homologous recombination Methods 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000012217 deletion Methods 0.000 description 18
- 230000037430 deletion Effects 0.000 description 18
- 238000001514 detection method Methods 0.000 description 18
- 239000003550 marker Substances 0.000 description 18
- 210000000688 human artificial chromosome Anatomy 0.000 description 17
- 210000001161 mammalian embryo Anatomy 0.000 description 16
- 108010006785 Taq Polymerase Proteins 0.000 description 15
- 238000003505 heat denaturation Methods 0.000 description 15
- 210000003411 telomere Anatomy 0.000 description 15
- 108091035539 telomere Proteins 0.000 description 15
- 102000055501 telomere Human genes 0.000 description 15
- 238000012546 transfer Methods 0.000 description 15
- 108090000631 Trypsin Proteins 0.000 description 14
- 102000004142 Trypsin Human genes 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 14
- 230000005945 translocation Effects 0.000 description 14
- 239000012588 trypsin Substances 0.000 description 14
- 210000004291 uterus Anatomy 0.000 description 14
- 241000282412 Homo Species 0.000 description 13
- 238000002105 Southern blotting Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000010276 construction Methods 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000011830 transgenic mouse model Methods 0.000 description 12
- 108010051219 Cre recombinase Proteins 0.000 description 11
- 101150066002 GFP gene Proteins 0.000 description 11
- 101150002896 RNR2 gene Proteins 0.000 description 11
- 230000036267 drug metabolism Effects 0.000 description 11
- 108700021672 human CYP3A Proteins 0.000 description 11
- 230000013011 mating Effects 0.000 description 11
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 11
- 229960001225 rifampicin Drugs 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 239000012980 RPMI-1640 medium Substances 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 102000054928 human CYP3A Human genes 0.000 description 9
- 238000002372 labelling Methods 0.000 description 9
- 238000007399 DNA isolation Methods 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 101100302211 Arabidopsis thaliana RNR2A gene Proteins 0.000 description 7
- 241000725101 Clea Species 0.000 description 7
- 102100039203 Cytochrome P450 3A7 Human genes 0.000 description 7
- 101000745715 Homo sapiens Cytochrome P450 3A7 Proteins 0.000 description 7
- 108700041567 MDR Genes Proteins 0.000 description 7
- 101100385057 Mus musculus Cyp3a25 gene Proteins 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 229950010131 puromycin Drugs 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 5
- 210000002459 blastocyst Anatomy 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 5
- 229940097277 hygromycin b Drugs 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 210000001853 liver microsome Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 101150003028 Hprt1 gene Proteins 0.000 description 4
- 238000010222 PCR analysis Methods 0.000 description 4
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 4
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 4
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000003209 gene knockout Methods 0.000 description 4
- 102000044284 human CYP3A4 Human genes 0.000 description 4
- 210000004754 hybrid cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000007857 nested PCR Methods 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 238000010079 rubber tapping Methods 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 101150116544 CYP3A4 gene Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241001635598 Enicostema Species 0.000 description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- 239000005662 Paraffin oil Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 101001136140 Pinus strobus Putative oxygen-evolving enhancer protein 2 Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000004507 artificial chromosome Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 230000010473 stable expression Effects 0.000 description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 2
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 101150092649 3a gene Proteins 0.000 description 2
- 101150044182 8 gene Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101100298359 Homo sapiens PPIF gene Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010027626 Milia Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100037392 Phosphoglycerate kinase 2 Human genes 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 101100202463 Schizophyllum commune SC14 gene Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000009319 interchromosomal translocation Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 101150077795 mdr gene Proteins 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 108010008054 testis specific phosphoglycerate kinase Proteins 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- XMWJVAGGHXKRKL-UHFFFAOYSA-N 2,2,2-tribromoethanamine Chemical compound NCC(Br)(Br)Br XMWJVAGGHXKRKL-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150107607 A4 gene Proteins 0.000 description 1
- 102100038820 Actin-related protein 2/3 complex subunit 1B Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101150061952 CYP3A7 gene Proteins 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 208000031639 Chromosome Deletion Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101150086858 Cyp3a25 gene Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 1
- 101000809459 Homo sapiens Actin-related protein 2/3 complex subunit 1B Proteins 0.000 description 1
- 101000981742 Homo sapiens Protein lifeguard 1 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 101150066553 MDR1 gene Proteins 0.000 description 1
- 238000003619 Marshal aromatic alkylation reaction Methods 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108700021154 Metallothionein 3 Proteins 0.000 description 1
- 102100028708 Metallothionein-3 Human genes 0.000 description 1
- 101100505385 Mus musculus Gpd1 gene Proteins 0.000 description 1
- 101100083090 Mus musculus Pgk1 gene Proteins 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000932075 Priacanthus hamrur Species 0.000 description 1
- 102100024139 Protein lifeguard 1 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101100310691 Rattus norvegicus Spata6 gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229940022682 acetone Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 101150027734 cript gene Proteins 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 231100001048 fetal toxicity Toxicity 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 108700028732 mouse CYP3A Proteins 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- -1 phosphoribosyl Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150116497 sacm1l gene Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- KUUVQVSHGLHAKZ-UHFFFAOYSA-N thionine Chemical compound C=1C=CC=CSC=CC=1 KUUVQVSHGLHAKZ-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a non-human animal into which a human chromosome fragment containing a cytochrome P450 gene group has been introduced, and a method for producing the same, for the purpose of supplying a non-human animal exhibiting a human drug metabolism.
- cytochrome P450 (hereinafter also referred to as “P450”) present in the liver.
- P450s form a superfamily consisting of many genes, and P450s with more than 40 homology in amino acid sequence are considered to be the same family, and those that show 55% or more amino acid homology even within the same family.
- Subgroups (Neson et al., Pharmacogenetics, 6: 1, 1996). Even if they belong to the same subfamily, differences in properties are observed when comparing human and rat P450s, and there may be differences in substrate substances and metabolites. Therefore, information on the metabolism of a certain drug cannot be directly applied to humans, and the development of a test system that accurately predicts the metabolism of drugs in humans is desired (Takue et al., Bioscience). And Industrie, 55:81, 1997).
- an in vitro system has been constructed to examine the effect of a drug metabolized and activated by P450 on living organisms. This is because the effects of metabolites metabolized outside the cells on the cells are examined by adding liver microsomes and drugs to the cell culture. Things. In this case, the activated substance adsorbs on the cell membrane, and only a part of the substance reaches the cell. Therefore, it may not be possible to accurately determine the effects of metabolites on cells. When cells express P450, it is thought that the drug that has entered without sorbing to the cell membrane is activated inside the cell, and it is thought that the effects of metabolites such as toxicity can be appropriately reproduced.
- any of the above methods using an in vitro expression system has some problems at present.
- an expression system using yeast into which human P450 has been introduced for example, Kovaleva et al., Biochem. Biophys. Res. Commun., 221: 129, 1996)
- the expression level of P450 can be obtained to some extent, without modifying P450 cDNA.
- the system contains yeast's own P450.
- An expression system using E. coli eg, Gillam et al., Arch. Biochem. Biophys., 305: 123, 1993
- E. coli eg, Gillam et al., Arch. Biochem. Biophys., 305: 123, 1993
- a system using human B lymphocytes may use human cells, It is considered that P450 is expressed in a state closer to the in vivo environment.
- P450 is expressed in a state closer to the in vivo environment.
- safety considerations must be taken (Takue et al., Bioscience and Industry, 55:81, 1997).
- a human P450 gene is introduced and an experimental animal is produced that produces the same metabolites as humans in the body, even if the metabolites are specifically produced in humans, the animal will not only be used for its pharmacological effects but also for its toxicity. It has a great advantage that it can be validated (Kamataki et al., Pharmacokinetics, 13: 280, 1998). For this reason, studies are being conducted on transgenic mice into which the P450 gene has been introduced. For example, Ramsden et al. Produced transgenic mice into which rat Cyp2B2 gene was introduced.
- Li et al. also produced transgenic mice having CYP3A7 that is specifically expressed in human fetuses (Li et al., Archs. Biochem. Biophys., 329: 235, 1996).
- the metallothionein promoter was used, and no tissue-specific induced expression of the P450 gene was observed.
- expression of the introduced CYP3A7 gene in the liver was observed, but in other lines, expression was observed in various organs. Therefore, it is considered that the melanin thionine promoter is not sufficient to express the P450 gene specifically in the liver.
- Cyp2el is known to be involved in the metabolism of acetaminophen, acetone, and arachidonic acid in addition to ethanol, but even homozygous individuals in which Cyp2el is completely deficient are apparently wild-type. Although it was not different from the mice of this study, the resistance to acetaminophen increased, and the results of pathological findings suggested that the metabolism by Cyp2el was greatly involved in the hepatotoxicity of acetaminophen. None of these P450 gene knockout mice were created to elucidate the function of the gene by gene knockout, and not to increase the expression level of the foreign P450 gene to be introduced. . Disclosure of the invention The present invention provides an improved model animal for examining drug metabolism in vivo based on the technical background as described above, particularly a model animal that retains the human P450 gene and performs human drug metabolism. The task is to
- the present inventors have succeeded in introducing a partial fragment of chromosome 7 derived from human normal fibroblasts into mouse ES cells (embryonic stem cells) by the microcell method, and obtaining a strain retaining the cells.
- mouse ES cells embryonic stem cells
- chimeric mice expressing human CYP3A4 genes in the liver and small intestine were obtained by drug induction, while retaining human chromosome fragments in normal tissues.
- a physical map of the Cyp3a gene group on mouse No. 5 chromosome was created, and a vector required for gene targeting was created based on the physical map. did.
- the present invention is as follows.
- a non-human mammal comprising at least one cytochrome P450 gene, wherein the gene is induced by a compound serving as a substrate for the gene product.
- the vector according to (13) is introduced into a mouse cell that retains pluripotency.
- a mouse cell which can be produced by the method of (14), wherein the cell lacks the Cyp3a gene group and retains pluripotency.
- mice or its progeny obtained by crossing the mouse or its progeny of (8) with the chimeric mouse or its progeny of (17) or the mouse or its progeny of (18).
- a human cytochrome P450 which is biologically active by culturing an individual, tissue or cell of the mouse or its progeny according to (8) and expressing the human cytochrome P450 gene retained by these.
- a biologically active cytochrome P450 By culturing an individual, tissue or cell of the mouse or progeny thereof according to (21) and expressing the cytochrome P450 gene retained by the mouse, a biologically active cytochrome P450 can be obtained.
- a method for producing a biologically active human cytochrome P450 which comprises producing the human cytochrome P450.
- the mouse of (8) or a descendant thereof, or the mouse of (21) or a mouse thereof A method for testing the pharmacological action and / or metabolism of a drug, which comprises administering the drug to progeny individuals, tissues or cells.
- the present invention also provides a non-human animal that holds at least CYP3A4 of the cytochrome P450 gene.
- the present invention provides a non-human animal holding at least CYP3A4, CYP3A5, and CYP3A7 of the human cytochrome P450 gene.
- the present invention provides a non-human animal having a human chromosome 7 fragment in which the CYP3A family of the cytochrome P450 gene is located.
- the present invention provides a human artificial chromosome comprising a human chromosome 7 fragment and a human chromosome 14 fragment in which the CYP3A family of the cytochrome P450 gene is located, and a non-human animal having the artificial chromosome. provide.
- cytochrome P450 may be simply referred to as “P450”. The outline of the present invention will be described below.
- the expression level, tissue specificity, and pattern of enzyme induction of the introduced gene should be such that the gene originally functions in humans. Needs to be reproduced as well.
- the transgene is not artificially modified as much as possible, and it is necessary to introduce the gene in a large unit including the expression control region.
- the method of gene transfer into mice is not particularly limited as long as they meet these requirements.
- a method using the YAC vector (Jakobobits et al., Nature, 362: 255, 1993, etc.) can be used.
- microcell fusion method for convenience in the present specification.
- each gene has at least partially a common function, and it is predicted that these functions complement each other. Rather, it is preferable to introduce each cluster.
- the microcell fusion method can Is advantageous.
- One specific embodiment of the present invention relates to introduction of a CYP3A gene group of a human P450 gene family into a non-human mammal.
- P450 belonging to CYP1 to 4 is involved in the metabolism of exogenous foreign substances including various drugs.
- the largest number of drugs that are metabolized by CYP3A4 are the largest, and the substrate selectivity is very broad (Tajie et al., Biosciences and Industries, 55:81, 1997).
- mice were prepared in which the chromosome 7 of human having the CYP3A gene group or a fragment thereof was introduced by the method described in W097 / 07671. Further, in a preferred embodiment, mouse CYP3A genes are efficiently expressed, and drug metabolism by the CYP3A genes on human chromosome 7 is made more human. Destroys endogenous Cyp3a genes. That is, the mouse gene is disrupted in the mouse into which the human gene has been introduced. Or, conversely, it is possible to introduce a human gene into a mouse in which the endogenous Cyp3a gene group has been disrupted. Furthermore, a desired mouse can also be obtained by crossing a mouse in which a human gene has been introduced and a mouse in which a mouse gene has been disrupted.
- the mouse endogenous Cyp3a gene group is considered to form a cluster on mouse chromosome 5 in the same manner as the human CYP3A gene group (for example, DR Nelson et al., Pharmacogenetics, 6: 1, 1996).
- Cyp3all, 13, 16 eg, DR Nelson et al., Pharmacogenetics, 6: 1-42, 1996)
- Cyp3a25 only the cDNA sequence is reported on the NCBI database. Have been.
- To completely destroy the mouse endogenous Cyp3a gene cluster at least these four genes must be destroyed.
- knockout In conventional gene disruption (knockout) methods (eg, Mansour et al., Nature, 336: 348, 1988), these four genes must be individually disrupted and at least four knockout experiments must be performed. No. When two or more genes are disrupted, if the target genes are physically separated from each other on the chromosome, knockout mice in which each has been disrupted are prepared and crossed to create multiple knockout mice. It is considered possible to generate knockout mice of the gene (eg, N. Longberg et al., Nature, 368: 856, 1994).
- the target gene Cyp3a gene group is a class Therefore, it is unlikely that the chromosomes are physically separated so that chromosome recombination due to crossover can occur during meiosis.
- knockout experiments were performed at least four times in the same mouse ES cells (eg, Evans et al., Nature, 292: 154, 1981). It is necessary to make a mouse.
- these four genes are not always sufficient to destroy the Cyp3a gene, and it is possible that an unidentified Cyp3a gene may still exist. Therefore, one must first determine how many Cyp 3a genes to destroy. Then, the same number of genes must be knocked out in the same ES cell.
- ES cells are embryonic undifferentiated cells that have totipotency to differentiate into all individual tissues, but naturally, the more cloning performed by knockout experiments, the more their totipotency is lost, especially for the transmission of progeny. There is also a risk that a useful chimeric mouse in which ES cells have differentiated into the germline of the mouse cannot be produced. From these facts, it is considered that disruption of the mouse endogenous Cyp3a gene group in the present invention is extremely difficult by the conventional method.
- a mutant mouse production system has been developed in which a recombinant enzyme Cre derived from Pacteriophage P1 is combined with its recognition sequence, a 34-mer ⁇ sequence.
- This system has been used primarily to conditionally make mutations (eg, Gu. H et al., Science, 265: 103, 1994). That is, when a certain gene region is to be deleted, the ⁇ ⁇ ⁇ sequence is first inserted into both ends of the gene region by homologous recombination, and recombination between the ⁇ sequences is performed only when the Cre enzyme is expressed. And the result is a deletion of the target gene region.
- the target gene is deleted at a specific time of development or in a specific tissue by controlling the Cre enzyme gene under the control of a development-specific or tissue-specific gene promoter. be able to. Furthermore, taking advantage of the high recombination efficiency between the ⁇ sequences, the target gene region is largely deleted (for example, ZW. Li et al., Proc. Natl. Acad. Sci. USA, 93: 6158, 1996). In the gene region deletion by ordinary homologous recombination, the recombination frequency decreases as the deletion region increases, and it is considered that the deletion up to about 20 kb is the limit. Cre- ⁇ ⁇ By using the system, it is becoming possible to delete a gene region of several hundred kb. That is, it is considered that not only one gene but also several adjacent genes can be deleted collectively.
- YAC vectors can clone large DNAs of up to 2 Mb and have been used exclusively for rough physical mapping at the chromosome level (for example, SW Scherer et al., Hum. Mol. Genet., 2: 751, 1993).
- genomic fragments having completely different positions on the chromosome at the time of cloning may be linked to each other and cloned into a vector (so-called YAC chimera), or the host yeast YACs are not very stable, as parts of the YAC may be deleted or recombination may occur during cultivation in culture.
- BAC Bacterial Artificial Chromosome
- the host is Escherichia coli, which is constructed based on F factor plasmid that exists in a single copy in the cells.
- the cloning size is about 300 kb at maximum, and 100-120 kb on average. In E. coli, it exists in a single copy, is very stable, and can be treated almost like a normal plasmid.
- the ability to perform sequencing means that a terminal probe (STS primer) can be prepared based on the terminal sequence of a BAC clone, and that screening of adjacent BAC clones can be performed easily. It means becoming. Due to these advantages, it is preferable to use this BAC system for preparing a physical map of the mouse Cyp3a gene cluster in the present invention.
- the following method can be considered as a specific physical map creation method using the BAC system.
- a PCR primer or hybridization probe capable of specifically detecting Cyp3all, 13, 16, 16 or 25 is prepared, and a mouse BAC library is screened.
- the end sequence of the obtained BAC clone is performed, a primer or a probe is prepared, and the BAC library is screened again. This screening is repeated several times to produce a BAC contig spanning several hundred kb.
- a full-length cDNA probe of any Cyp3a gene was prepared, and the obtained BAC contig was subjected to mild conditions (at least Cyp3all, 13,16,25).
- Hybridization is performed under the condition that the BAC clone containing the positive becomes positive). Out of the BAC contigs that are positive with this probe, the outermost BAC clone is considered to correspond to both ends of the class. Once both ends of the class have been determined by this method, it is possible to delete all of the unknown Cyp3a genes in the class at once.
- the genomic DNA corresponding to both ends of the class is cloned to prepare an actual evening targeting vector.
- This vector contains the ⁇ sequence as described above, and can be inserted into both ends of the cluster by homologous recombination in ES cells.
- transfection of the Cre expression vector into the ES cells results in recombination at both ends of the cluster by the Cre-loxP system, resulting in the deletion of the Cyp3a gene cluster. It is not possible to predict how efficiently the Cre-loxP system will cause a class-one deletion that is expected to span hundreds of kb.
- Chromosome 12 and chromosome 15 were successfully translocated to each other using the Cre-loxP system. They express the 5 '(including ⁇ ) and 3' (including ⁇ ) and 3 '(including ⁇ ) of the Hprt gene to ES cells lacking the Hprt (hypoxanthine, guanine, phosphoribosyl, transferase) gene. It was inserted into a specific region of chromosome No. 15 and 15 by homologous recombination. The Hprt gene is reconstituted only when Cre is expressed and recombination occurs between ⁇ , and the ES cells can grow in a hypoxanthine-free medium (HAT medium). This selection method can be used only for Hprt gene-deficient ES cells, and cannot be used for any ES cells. Therefore, in the present invention, the following selection method was considered so that the method can be used for any ES cells.
- HAT medium hypoxanthine-free medium
- the GFP (Green Fluorescent Protein) gene derived from O jellyfish has been developed as a repo overnight gene for gene transfer into animal cells (for example, Prasher, DC, et al., Gene, 111: 229, 1992).
- GFP emission does not require a substrate and can be detected by fluorescence, allowing live cells to be monitored in a short time. This is also considered important in maintaining the totipotency of ES cells.
- the GFP gene was used as a positive selection marker for the recombinant. Specifically, a GFP gene that does not contain a promoter is inserted into one end of the Cyp3a cluster, and a promoter required for GFP expression is inserted into the other end. When recombination between the ⁇ sequences by Cre occurs, the promoter is linked to the GFP gene, and GFP is expressed. The recombinant ES cells emit fluorescence, which allows for selection.
- a chimeric mouse is prepared from the obtained ES cells (Cyp3a gene class Yuichi is heterologously deleted) and is mated with a wild mouse to obtain an F1 mouse heterozygously deleted in Cyp3a gene class Yuichi.
- a chimeric mouse harboring a human chromosome 7 fragment and a wild-type mouse The mouse is crossed to obtain an F1 mouse retaining a human chromosome 7 fragment.
- This F1 mouse is mated with the above-mentioned F1 mouse in which the Cyp3a gene cluster 1 is heterologously deleted to obtain an F2 mouse in which the Cyp3a gene cluster is heterologously deleted and which retains a human chromosome 7 fragment. .
- mice will be described as non-human mammals, but the present invention is not limited to mice.
- a mouse chromosome containing a human P450 gene group or a fragment thereof is retained in a form capable of being expressed on its own chromosome, and furthermore, a mouse individual deficient in a mouse endogenous P450 gene group, which is a counterpart, is:
- human P450 gene a mouse into which a human P450 gene or a P450 gene group has been introduced, or a mouse lacking a mouse endogenous P450 gene group, is referred to as “human P450 gene”.
- Transgenic mice ".
- an example of a method for producing a human P450 transgenic mouse will be described in detail for each step.
- the chromosome donor cell it is desirable to have 1) a human chromosome labeled with a marker selectable in a recipient cell, 2) no other human chromosome, and 3) a high microcell-forming ability.
- any cell line derived from human, cancer cells, or primary cultured cells can be used, but the possibility of abnormalities such as chromosome deletion and amplification is low, and culture is easy. Considering the points, normal fibroblasts are suitable.
- human cells can be transformed with a vector expressing a marker gene such as drug (G418, puromycin, hygromycin, blasticidin) resistance.
- a promoter for controlling the expression of the marker used herein one that works efficiently not only in human cells but also in recipient cells such as mouse ES cells is desirable.
- the SV40 enhancer and the herpes simplex virus thymidine kinase promoter were linked (Katoh et al., Cell Struct. Funct., 12: 575, 1987), the mouse PGK-1 promoter (Soriano et al., Cell, 64: 693, 1991).
- a DNA fragment containing the above marker gene and, if necessary, a marker gene linked to a promoter is used to transform human cells by electoporation (Ishida et al., Introduction to Cell Engineering Laboratories, Kodansha, 1992) and the like. By selecting cells to be expressed, it is possible to obtain a library of human cell transformants in which the introduced marker genes have been randomly inserted into 46 human chromosomes of 23 species.
- the above transformants can be transformed into cells having high microcell-forming ability, for example, mouse A9 cells (Oshimura, M., Environ. Health Perspect). , 93:57, 1991), the ability to form microcells can be imparted.
- mouse-human hybrid cells It is known that the human chromosome is selectively lost, but the fusion strain obtained here can stably maintain the masked human chromosome by selecting with the aforementioned marker. be able to.
- microcells from this cell fusion strain and to fuse them again with mouse A9 cells. Also in this case, it is considered that most of the obtained microcell fusion strains satisfy the conditions of 1), 2), 3) by selecting with the marker on the human chromosome. Identification of the marked human chromosome was performed by PCR (polymerase chain reaction, Sakaki et al., Science, 239: 487, 1988), Southern blot analysis (Ausubel et al., Current protocols in molecular biology, John Wily & Sons, Inc., 1994) and FISH (fluorescence sense in situ hybridization, Lawrence et al., Cell, 52:51, 1988) analysis.
- the above process is repeated for many human cell transformant clones to search for a target chromosome that has been marked.
- the above-described process may be performed on a mixture of human cell-transformed clones, and the chromosome containing the human P450 gene may be identified from the resulting large number of mouse-human monochromosomal hybrid cells.
- chromosomes containing the marked human P450 gene can be fragmented and introduced into mouse A9 cells. Even when the microcell is not irradiated with gamma rays, a chromosome containing a partially fragmented human P450 gene may be transferred at a certain rate. In these cases, the resulting microcell fusion strain retains a fragment of the chromosome containing the marked human P450 gene. These can be used when it is desired to introduce a partial chromosome fragment containing the human P450 gene into a recipient cell.
- Human chromosomes to be introduced into recipient cells such as mouse ES cells contain deletion, translocation, substitution, inversion, doubling, etc., as long as the target cytochrome P450 gene can be introduced.
- Various modifications can be made. Previously, accidentally fragmented human chromosome fragments or the entire human chromosome itself were used for introduction into mice, such as human antibody-producing mice prepared by Tomizuka et al. (Nature Genet., 16: 133-143, 1997).
- human chromosomes should be prepared at desired sites rather than accidentally generated chromosome fragments. Techniques for freely processing chromosomes, such as cutting or connecting only desired chromosome fragments to another stable chromosome, are desired.
- Such a technique is called chromosome engineering and mainly involves cutting the endogenous mouse chromosome site-specifically in mouse ES cells (W098 / 54 348) or recombining (translocation) between homologous chromosomes. This has led to the deletion, inversion and doubling of specific gene regions, and has been used to generate mutant mice having such modified chromosomes (R. Ramirez-Solis et al., Nature 378: 720, 1995). On the other hand, there has been no report on the production of non-human animals such as mice carrying human chromosomes subjected to such various artificial modifications.
- # 7-HAC a human artificial chromosome carrying a human chromosome 7 fragment
- the human CYP3A gene cluster is located at 7q21-22 on chromosome 7 (eg, BABrooks et al., Am. J. Hum. Genet., 43: 280, 1988).
- a human telomeric sequence is inserted by homologous recombination into a chromosome site (for example, ARC41, etc.) located on the extreme telomere side of the CYP3A gene cluster, and telomere truncation is performed.
- a chromosome site for example, ARC41, etc.
- the human chromosome 7 fragment containing the CYP3A gene cluster may further contain the MDR gene cluster (PGY1,3).
- the MDR gene cluster (PGY1, 3) exists on the extreme centromeric side of the CYP3A gene cluster (NCBI database).
- the MDR1 gene is a gene involved in the extracellular excretion of drugs (eg, Juliano, RL et al., Biochemi. Biophys. Acta. 455: 152, 1976), and it has been reported that there are species differences for specific drugs ( For example, Lecureur V. et al., Carcinogenesis, 17: 1157, 1996). Since most of the substrate for CYP3A4 is also a substrate for MDRl (for example, Schuetz.
- the ⁇ sequence which is a recognition sequence of the recombinase Cre, was inserted by homologous recombination into a chromosomal site (eg, AC004082 NCBI database) located at the extreme center of the MDR gene class.
- a chromosomal site eg, AC004082 NCBI database
- -Use only CYP3A fragment for artificial chromosome production.
- the homologous gene of the host animal be deleted or inactivated in the MDR gene.
- Mdr gene-deficient mice can be generated according to the methods described in these articles.
- the mouse Cyp3a gene class and the mouse Mdrla and / or Mdrlb genes were homozygously deleted, and the human CYP3A gene cluster and the human MDR gene cluster were deleted.
- a mouse having a chromosome fragment containing is obtained.
- SC20 fragment of human chromosome 14 was retained almost 100% in mice and transmitted to offspring. (W098 / 37757). Therefore, in the present invention, it is considered that this SC20 is used as a human artificial chromosome vector. That is, by translocating the CYP3A human chromosome 7 fragment described in (i) above to SC20, a human artificial chromosome # 7-HAC holding a human chromosome 7 fragment is constructed. 1 Located at 14pl2 on chromosome 4.
- nitrile DT40 cells RIKEN cell bank: RCB1464, ATCC: CRL-2111
- host cells for efficient homologous recombination described in (i) and (ii) above (Eg, Dieken et al., Nature Genet., 12: 174, 1996).
- DT40 cells an example using DT40 cells will be described. Although the efficiency of ES cells is lower than that of DT40 cells, homologous recombination is possible.
- DT40 cells are prepared that retain the modified human chromosome 7 fragment obtained as shown in (i) and (ii) above and that of the modified SC20.
- DT40 cells carrying each modified human chromosome fragment were fused.
- Cre recombinase is expressed and translocated in this DT40 cell hybrid, but the frequency of recombination (translocation) between two heterologous chromosomes is reported to be extremely low.
- the translocation is between exogenous human chromosomes, not endogenous chromosomes.
- the recombination efficiency may be reduced. Therefore, it is preferable to consider a positive selection system that can select cells in which recombination has occurred between loxPs as expected.
- the GFP gene is expressed in cells in which chromosomal translocation has occurred between loxPs, and FACS Use a system that clones the target cells by sorting the cells. Furthermore, in order to increase the frequency of recombination, Cre recombinase is expressed stably, not transiently. Translocation between the two chromosomes occurs reciprocally, so when Cre recombinase is stably expressed, the chromosome that has translocated with great effort recombines again (although less frequently). To There is a possibility to return.
- Cre recombinase is transiently expressed, or the expression of Cre recombinase is strictly controlled.
- the human artificial chromosome translocated immediately after translocation in the DT40 hybrid is transferred to Chinese hamster CH0 cells by the microcell fusion method. It is not affected by enzymes. Therefore, it is possible to simply express Cre recombinase stably.
- human chromosome fragments of any size can be obtained by using telomere truncation and interchromosomal translocation by the Cre-- ⁇ system in chicken DT40 cells. (More than the YAC vector cloning size) can be cloned into the stable ⁇ site (14pl2) on the SC20 chromosome vector, and a human artificial chromosome construction system is proposed.
- # 7-HAC produced by the above human artificial chromosome construction system should be introduced into Chinese Hams Yuichi CH0 cells before being introduced into mouse ES cells.
- Dieken et al. (Nature Genet., 12: 174, 1996) transferred modified human chromosomes from mouse DT40 cells to mouse MEL cells (a type of cancer cell), but most of them were fragmented. Populated in state.
- the present inventors have also attempted transfer of human chromosomes from chicken DT40 cells to mouse A9 cells, etc., but fragmentation of all human chromosomes was observed, and transfer was not intact. However, the inventors have first found that human chromosomes can be transferred intact only when transferred to Chinese hamster CH0 cells.
- # 7-HAC produced by the human artificial chromosome construction system was once transferred to CH0 cells. It is known that CH0 cells form microcells as efficiently as mouse A9 cells (for example, M. Koi et al., SCIENCE 260: 361, 1993), whereby modified human chromosomes are converted from CH0 cells. It is considered that the cells can be transferred into mouse ES cells to produce chimeric mice retaining # 7-HAC. The outline of the above procedure is shown in Figure 16.
- embryonic carcinoma cells from various strains of mice (EC cells, Hanaoka et al., D ifferentiation, 48:83, 1991), embryonic stem cells (ES cells, Evans et al., Nature, 292: 154, 1981), embryonic germ cells (EG cells, Matsui et al., Cell, 70: 841, 1992)
- EC cells Hanaoka et al., D ifferentiation, 48:83, 1991
- embryonic stem cells ES cells, Evans et al., Nature, 292: 154, 1981
- embryonic germ cells EG cells, Matsui et al., Cell, 70: 841, 1992
- ES and EG cells have a particularly high ability, often contribute to germ cells, and can produce progeny derived from the cells.
- EC cells are mainly obtained from germ cell carcinomas
- ES cells are obtained from the inner cell mass of blastocysts
- EG cells are obtained from primordial germ cells that appear early in development.
- the recipient cells of the chromosome transfer containing the human P450 gene in the present invention include these cell lines and mutants thereof, and any undifferentiated cells capable of differentiating into all or some normal cells in a mouse individual. Can be used.
- a microcell prepared from the chromosome donor cell containing the human P450 gene obtained in (1) or a microcell irradiated with gamma rays can be used. Transfer to the recipient cell is performed by fusing the recipient cell and the microcell by the method described in (Seiki Hydrogen Co., Cell Engineering Handbook, Yodosha, 1992).
- chromosomes containing the human P450 gene or fragments thereof carry a selectable marker in recipient cells.
- the human P450 gene can be obtained by selecting a strain that retains the chromosome containing the human P450 gene or the human P450 gene or a fragment thereof by PCR, Southern plot analysis, FISH analysis, etc., as in (1). It is possible to introduce a chromosome or a fragment thereof containing In addition, by sequentially introducing chromosomes or fragments thereof containing a plurality of human P450 genes carrying different selectable markers, it is possible to obtain recipient cells which simultaneously carry these.
- Recipient cells selected by markers on the chromosome containing the human P450 gene retain all or part of the chromosome containing the human P450 gene or the human P450 gene that the donor cell had. Is confirmed as follows. Using genomic DNA extracted from the selected recipient cells, human-specific repetitive sequences (Ll, Alu et al., Korenberg et al., Cell, 53: 391, 1988) and human chromosome-specific probes (Lichter et al. Human Genetics, 80: 224, 1988) Detected by chromosome analysis such as lettuce in situ hybridization (FISH), PCR using human P450 gene-specific primers, and Southern analysis using a human P450 gene-specific sequence probe.
- FISH lettuce in situ hybridization
- a chimeric mouse is prepared from a mouse cell line such as the ES cell line obtained in (2) by a method described in (Shinichi Aizawa, Bio Manual Series 8 Gene Setting, Yodosha, 1995). It is desirable to use the conditions already examined for each ES cell line for selection of the development time and strain of the host embryo for efficient chimeric mouse production. For example, for TT2 cells derived from CBAXC57BL / 6F1 (wild color, Yagi et al., Analytical Biochemistry, 214: 70, 1993), the 8-cell stage derived from Balb / c (white, CLEA Japan) or ICR (CLEA Japan) It is desirable to use embryos as host embryos.
- the contribution rate of ES cells in mice born from embryos injected with ES cells can be roughly determined by their coat color. However, just because there is no contribution to coat color does not mean that there is no contribution from other organizations. More detailed retention of human chromosomes in each tissue of the chimeric mouse can be confirmed by Southern analysis, PCR, etc. using genomic DNA extracted from each tissue.
- Expression of the human P450 gene on the introduced chromosome is confirmed as follows. Expression of mRNA derived from chromosomes including the human P450 gene was determined by RT-PCR using RNA from each tissue (Kawasaki et al., Proc. Natl. Acad. Sci. USA, 85: 5698, 1988), Northern blot method. (Ausubel et al., Supra). Expression at the protein level is detected by the Western blot method (Ausubel et al., Supra), or by measuring testosterone 6-hydroxylation activity using chimeric mouse liver microsomes.
- the retention of the chromosome containing the human P450 gene group and the expression of the gene on the chromosome in the chimeric mouse cells can be confirmed by the appearance of resistant cells due to the expression of the drug resistance marker gene in the primary culture cells derived from the chimeric mouse.
- ES cells carrying the chromosome containing the human P450 gene group in chimeric mice are differentiated into germ cells of the chimeric mouse, chromosomes containing the introduced human P450 gene group or fragments thereof are also found in their progeny. Express the gene on that chromosome or fragment.
- Cyp3a cluster which is a counterpart of the introduced human P450 gene group
- sequence order of each Cyp3a gene in the cluster that is, a physical map You need to decide.
- a system with a small cloning size such as plasmid is inappropriate, and a system capable of cloning huge DNA is indispensable.
- a YAC for example, SW Scherer et al., Human Synthetic Chromosome
- a yeast artificial chromosome capable of cloning a DNA with a cloning size of about 40 kb or up to 2 Mb of DNA.
- the BAC vector is effective in chromosome walking and large-scale genome sequencing in that the end sequence of the inserted DNA can be easily performed. Using these vector systems, a physical map of the mouse endogenous Cyp3a cluster on the chromosome can be generated.
- creation of a physical map using a BAC vector can be performed as follows.
- a PCR primer or a probe for hybridization can be prepared that can specifically detect each of the mouse Cyp3a genes (Cyp3all, 13, 16 and 25), and a commercially available mouse BAC library can be screened.
- Perform a terminal sequence of the obtained BAC clone prepare primers or probes, and re-run BAC live. Rally screening. By repeating this terminal sequence and screening several times, a BAC contig spanning several hundred kb can be produced.
- a full-length cDNA probe of any mouse Cyp3a gene is prepared, and the obtained BAC contig is subjected to hybridization under mild conditions.
- BAC clones containing at least one of the four genes identified to date, Cyp3all, 13, 16 and 25, be positive.
- the clone located outside the contig most corresponds to both ends of class I, and it is possible to complete the physical map of class I. Alternatively, this can be achieved by determining the entire sequence of this BAC contig, as is done in the genome project.
- genomic DNA corresponding to both ends of the cluster can be cloned to create an actual targeting vector.
- This vector contains the loxP sequence as described above, and can be inserted into both ends of the class by homologous recombination in ES cells.
- transfection of the Cre expression vector into the ES cell causes recombination at both ends of the cluster by the Cre-loxP system, resulting in the deletion of the Cyp3a gene class. it can.
- a yeast FLP / FRT system (eg, S. Jung et al., Science, 259: 984, 1993) can be used. If a cluster that is expected to span hundreds of kb is deleted by the Cre-loxP system, it is not possible to predict how efficiently the deletion will occur.
- GFP gene expression can be used as a marker. Specifically, a GFP gene that does not contain a promoter is inserted into one end of the Cyp3a class, and a promoter required for GFP expression is inserted into the other end. When recombination between the ⁇ sequences by Cre occurs, the promoter and the GFP gene are linked, and GFP is expressed. Such recombinant ES cells emit fluorescence So, selection becomes possible.
- a certain drug resistance gene As another selection marker, it is possible to use a certain drug resistance gene.
- a drug resistance gene is expressed, and the recombinant ES cells can be selected in a selective medium containing the drug.
- a selection method that does not significantly affect the totipotency of ES cells is desirable.
- the targeting vector prepared in (6) is introduced into mouse cells that retain pluripotency, for example, ES cells.
- ES cells for example, ES cells.
- Cre- ⁇ ⁇ system is used to delete genes for each cluster, homologous recombination by PCR, Southern analysis, etc., will be performed every time the ⁇ sequence is introduced upstream and downstream of one cluster. It is desirable to confirm that ES cells have occurred and to confirm whether the ES cells have pluripotency.
- a chimeric mouse is produced using an ES clone having a ⁇ sequence obtained by homologous recombination in the genome, into which each vector is introduced, and the production efficiency is examined.
- the vector that expresses the Cre enzyme is introduced by electroporation into ES cells that have a 1 oxP sequence at each end of the mouse endogenous Cyp3a gene class.
- Cre does not necessarily need to be integrated into the mouse genome, but may be a promoter or a vector structure that is expressed temporarily. Ultimately, selection of ES cells in which the Cyp3a gene is defective as a cluster is convenient not only by direct analysis of genes such as PCR and Southern analysis, but also by selection using reporter genes such as GFP. is there.
- the production of the knockout mouse is the same as the method (3) described above.
- mice that retain human chromosomes containing human P450 genes and lack mouse endogenous P450 genes
- a human P450 mouse that has a human chromosome containing the human P450 gene group and lacks the mouse endogenous P450 gene group can be a chimeric mouse or a chimeric mouse that has the human chromosome containing the human P450 gene group that has been prepared by the method described above. It is obtained by crossing offspring with a chimeric mouse in which the endogenous mouse P450 gene has been deleted for each cluster or its offspring. Both "retention of the human chromosome" and “deficiency of the endogenous P450 gene” are considered to be transmitted by genetic elements of both, basically according to Mendel's law. Various patterns are conceivable for the mouse mating method, and the method can be specifically implemented as follows.
- a chimeric mouse having a heterozygous deletion of the Cyp3a gene cluster is mated with a wild mouse to obtain an F1 mouse having a heterozygous deletion of the Cyp3a gene class Yuichi (F1 mouse A).
- F1 mouse A a chimeric mouse retaining a human chromosome 7 fragment and a wild-type mouse are bred to obtain an F1 mouse retaining a human chromosome 7 fragment (F1 mouse B).
- the F1 mouse A and the F1 mouse B are bred to obtain an F2 mouse lacking the heterozygous Cyp3a gene cluster and retaining a human chromosome 7 fragment.
- the final mouse is obtained.
- a biologically active human P450 protein can be obtained from its organs, tissues and cells.
- a human P450 protein can be extracted by extracting and purifying a fraction containing human P450 from liver microsomes of the chimeric mouse or its progeny.
- a human P450 protein can be recovered from a culture by establishing and culturing a cell line from a tissue of a chimeric mouse having a chromosome containing the human P450 gene or its progeny and culturing it.
- human P450-introduced mice obtained by crossing the obtained chimeric mice or their progeny, or knockout mice deficient in the mouse endogenous P450 gene group, can be used in vivo in humans. Since it is thought that human P450 is expressed in the same pattern as that of expression, administration of a specific drug can be used as an experimental animal to study pharmacological effects, toxicity, and pharmacokinetics at the individual level. High utility value.
- FIG. 1 is an electrophoresis photograph of RT-PCR using RNA derived from liver of a chimeric mouse administered with rifampicin. It has been shown that human CYP3 A4 is expressed in the liver of chimeric mice to which rifampicin was administered.
- FIG. 2 is an electrophoresis photograph (RT-PCR) showing the results of examining the expression of human CYP3A4 in various organs of a chimeric mouse administered with rifampicin. 2 shows that human CYP3A4 is expressed in liver and small intestine.
- FIG. 3 shows contig production of BAC clones containing mouse Cyp3all, 13, 16, 25.
- FIG. 4 is a diagram showing the structure of cassette vectors ploxPUP and ploxPDOWN for inserting ⁇ sequences at both ends of the Cyp3a gene class.
- FIG. 5 shows a scheme of evening targeting to the mouse Cyp3a region.
- FIG. 6 is a diagram showing the structure of a targeting vector ploxP3aUP for deleting a mouse Cyp3a gene class.
- FIG. 7 is a diagram showing the structure of the evening getter vector plox3aD0WN for deleting the mouse Cyp3a gene class.
- FIG. 8 is a diagram showing the structure of cassette vectors ploxPHyg and ploxPbsr for inserting a sequence into a human chromosome.
- Figure 9 shows the structures of the targeting vectors pBSC0LlA21ox (F) and pBSCOLlA21ox (R) for inserting the ⁇ sequence into the genomic region (C0L1A2) located at the C0L1A2 locus on human chromosome 7, and the homologous set. It is a figure which shows the identification of a recombinant.
- FIG. 10 is a diagram showing the structure of a cassette vector pTELPuro for inserting a human telomeric sequence into a human chromosome.
- FIG. 11 shows an evening getter vector for inserting a human telomere sequence into the genomic region (AF006752) located in the CYP3A locus cluster 1 on human chromosome 7 pTEL Puro5.3 (F), pTELPuro5.3 (R)
- Fig. 3 is a view showing the structure of and the identification of homologous recombinants.
- FIG. 12 is a diagram showing the presence of genes and polymorphic markers on human chromosome 7 and the construction of human artificial chromosome # 7-HAC.
- FIG. 13 is a diagram showing the structure of the evening targeting vector pRNR21oxPbsr for inserting the ⁇ sequence into the RNR2 locus on human chromosome 14 and the identification of homologous recombinants.
- FIG. 14 is a diagram showing the structure of the Cre recombinase stable expression vector pBS185hisD.
- FIG. 15 is a diagram showing detection of site-specific translocation of human chromosome 7 fragment to chromosome 14 fragment SC20.
- FIG. 16 is a diagram showing an outline of production of a chimeric mouse having # 7-HAC.
- BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.
- Example 1 Screening of Mouse A9 Cells Carrying Human Chromosome 7 Fragment
- a mouse A9 cell library carrying various human chromosomes was prepared according to the method described in W097 / 07671. Specifically, the measurement was performed as described below.
- Plasmid pSTneoB containing the G418 resistance gene (Katoh et al., Cell Struct. Funct., 1: 575, 1987; Japanese Collection of Research Biologicals (JCB), Deposit Number: VE039) is linearized with the restriction enzyme Sail (Takara Shuzo).
- the cells were transformed into human normal fibroblasts (HFB-KRIKEN Cell Bank, RCB0251).
- HFL-1 cells are treated with trypsin, suspended in Dulbecco's phosphate buffer (PBS) to a concentration of 5 ⁇ 10 6 cells / ml, and then used with Gene Pulser (BioRad) in the presence of 10 ⁇ g DNA.
- PBS Dulbecco's phosphate buffer
- Mouse A9 cells (Oshimura, Environ. Health Perspect., 93:57, 1991, JCRB0211) supplemented with Dulbecco's modified Eagle's medium (DM) supplemented with 10% fetal bovine serum (FBS).
- DM Dulbecco's modified Eagle's medium
- FBS fetal bovine serum
- EM in a 100 mm Petri dish.
- 52 groups of G418-resistant HFL-1 cells were cultured in F12 supplemented with 15% fetal bovine serum (FBS) and 200 g / ml G418, each in a 100 mm Petri dish.
- Mouse A9 cells and HF-1 cells were mixed with trypsin and mixed in quarter to half volumes, seeded in 100 mm dishes, added with 10% fetal bovine serum (FBS) in DMEM and 15% fetal bovine serum (FBS). ) was cultivated for half to one day in an equal mixture with F12.
- FBS fetal bovine serum
- FBS fetal bovine serum
- Cell fusion followed the method described in (Shimizu et al., Cell Engineering Handbook, Yodosha, p.127-, 1992). After washing the cell surface twice with DMEM, the cells were treated with 1 ml of PEG (1: 1.4) solution for 1 minute, and further replaced with 2 ml of PEG (1: 3) solution for 1 minute.
- the PEG solution was aspirated, washed three times in serum-free medium (DMEM), and then cultured in normal medium (10% FBS, DMEM) for one day.
- DMEM serum-free medium
- the cells were dispersed by trypsin treatment, Uwabain (1x10- 5 M, Sigma) and suspended in G418 (800 ⁇ G / ml) double selection medium containing (10% FBS, DMEM), seeded in three 100 negation dish did. After culturing for about 3 weeks, the resulting colonies were dispersed by trypsinization, and cultured in a selective medium (10% FBS, DMEM) containing G418 (800 ⁇ g / ml).
- a culture solution (20% FBS, DMEM) containing colcemide (0.05 ⁇ g / ml, demecorsin, Wako Pure Chemical) and cultured for 2 days to form microcells.
- microcell was suspended in a serum-free medium, filtered through a filter and purified. Purified micronuclei were added to a 25 cm 3 flask in which mouse A9 cells were cultured to 80% saturation, and fused with a PEG solution. The cells were cultured in a selective medium containing G418, and colonies were isolated.
- Human CYP3A gene class exists in the mouse A9 cell library.
- a clone retaining the chromosome 7 fragment was identified by PCR using a primer capable of specifically detecting the human CYP3A4 gene as follows.
- PCR cycle conditions were as follows: heat denaturation at 94 ° C for 1 minute, and then 35 cycles of 98 ° C for 10 seconds, 65 ° C for 30 seconds, and 72 ° C for 1 minute. As a result, 20 positive clones were obtained.
- clones H5 and Z9 were considered to retain the full length of chromosome 7.
- clone E22 was considered to retain a fragment containing only the vicinity of CYP3A4.
- FISH analysis was performed using human COT-1 DNA as a probe. The method followed the method described in W097 / 07671. As expected from the PCR results, it was revealed that the full-length human chromosome 7 was independently present in clone H5, and a small human chromosome 7 fragment was independently present in clone E22.
- the clones H5 and E22 were used as human chromosome 7 (fragment) donor cells.
- A9 cells donating microcells were cultured under the following conditions.
- Mouse A9 cells (E22) having human chromosome 7 marked with the G418 resistance gene were treated with 10% fetal fetal serum (hereinafter abbreviated as “FBS”; Sigma) and G418 (800 ⁇ g / ml, Dieneti).
- FBS fetal fetal serum
- G418 800 ⁇ g / ml, Dieneti
- the culture was performed on Dulbecco's modified Eagle medium (hereinafter abbreviated as “DMEM”.
- ES cells T2F, Lifetech's Oriental
- MH cells microcell-fused ES cells
- Culture of ES cells 20% FBS (Gibco), 10 ⁇ M non-essential amino acids (Gibco), 10- 4 M 2-mercaptoethanol (Sigma), 1 0 3 ULIF (leukocyte growth inhibitory factor, Gibco) was added DMEM (hereinafter, abbreviated as “DMEM for ES”) was used.
- ES cells were seeded in a 35-min dish (coning) in which seed cells (Neo-resistant primary cultured cells, Lifetech Oriental) treated with mitomycin C (Sigma) were seeded in advance and cultured.
- the DMEM for ES was changed every 12 hours. Passaging was performed every two days when the cell density of ES cells reached 80% saturation. After aspirating the DMEM for ES from the dish, the dish was washed three times with EDTA-PBS, and treated with 0.7 ml of 0.25% trypsin (Gibco) for 15 minutes. Stop the trypsin reaction by adding DMEM for ES to the dish, and pipette the cell suspension with a Gilson Pipetman (P-1000) into a 15 ml tube.
- P-1000 Gilson Pipetman
- the microcell was obtained by the following procedure. E22 cells were cultured in 24 25 cm 2 flasks (3025, 1 course) until the cell density reached 90% saturation. The culture solution was replaced with a culture solution (20% FBS, DMEM) containing colcemide (0.06 ⁇ / ⁇ 1, demecorsin, Wako Pure Chemical) and cultured for 2 days to form microcells. The culture solution was removed from the flask, and the flask was filled with DMEM containing cytochalasin B (10 ⁇ g / ml, Sigma) solution which had been kept at 37 ° C. in advance until the flask was almost full.
- DMEM containing colcemide (0.06 ⁇ / ⁇ 1, demecorsin, Wako Pure Chemical
- the container After inserting the flask into an acrylic centrifuge container and injecting hot water (34 ° C), the container was set in a rubber adapter and centrifuged at 8000 rpm for 1 hour at 34 ° C. After centrifugation, DMEM containing cytochalasin B was removed, and the microcells accumulated at the bottom of the flask were suspended in DMEM and collected.
- the collected microcell suspension was filtered in the order of a filter having a pore size of 8 // m, 5 ⁇ m, and 3 ⁇ m on the filter membrane to purify the microcell. ⁇ ⁇ Centrifuge the prepared microcells at 1500 rpm for 10 minutes, resuspend them in 5 ml of DMEM, centrifuge again at 1500 rpm for 5 minutes, and centrifuge the tubes at 4 ° C without removing the supernatant. Was served.
- Microcell fusion was performed in the following procedure. 60mni dish (Corning) Two ES cells were washed three times with EDTA-PBS, treated with trypsin to detach the cells from the dish, suspended in DMEM for ES, and collected in a 15ml tube. After centrifugation at 1500 rpm for 5 minutes to collect cells, the supernatant was aspirated. After tapping the tube, the cells were washed three times with DMEM. After washing, the cells were resuspended in 5 ml of DMEM, gently layered on the previously collected microcell solution, and centrifuged at 1250 rpm for 5 minutes.
- DMEM containing PEG1500 polyethylene glycol, Wako Pure Chemical Industries
- PEG1500 polyethylene glycol, Wako Pure Chemical Industries
- DMEM for ES with G418 DMEM for ES with G418
- Eneticin and Gibco an effective concentration of 150 ⁇ g / ml
- the emerged G418-resistant clone was isolated and seeded on a 24-well plate (coining) that had been seeded with feeder cells, and then cultured in the order of a 12-well plate (coining) that had been seeded with feeder cells, followed by 35 recommended dishes.
- the scale has been increased.
- Genomic DNA was extracted from these clones using the Puregene DNA Isolation Kit (Gentra System) and subjected to PCR analysis. PCR was performed using the extracted genomic DNA as type III and a primer prepared for the purpose of detecting CYP3A family genes (CYP3A4, CYP3A5, CYP3A7). Thus, a clone having human chromosome 7 containing the CYP3A family gene was identified.
- primers for detecting CYP3A4 the primers of SEQ ID NOS: 1 and 2 described above were used.
- the primer sequence for detecting CYP3A5 and CYP3A7 the sequences shown below were used.
- Antisense 5,-TCAGCTGTGTGCTGTTGTTTGC-3, (SEQ ID NO: 4)
- Antisense 5'-GAGTTAATGGTGCTAACTGGGG-3 '(SEQ ID NO: 6)
- PCR reaction solution 10 X Ex Taq Buffer (Takara Shuzo) 3 ⁇ 1, dNTP (dATP, dGTP, dCTP and dTTP, 2.5 mM each) (Takara Shuzo) 4.8 ⁇ 1, each primer 10 pmol, genomic DNA lOOng , Ex Taq (5U / ml) (Takara Shuzo) 0.5 1 was added to sterilized distilled water to make a total of 30 1 and dispensed into PCR tubes (PerkinElmer 1). All operations in the process of preparing the PCR reaction solution were performed on ice.
- Example 3 Production of chimeric mice using ES cells carrying the human chromosome 7 fragment containing the CYP3A family gene
- MH cells carrying the human chromosome 7 obtained by microcell fusion a human containing the CYP3A family gene was used.
- a mouse having a chromosome 7 fragment in somatic cells was produced.
- the method for culturing MH cells was the same as the method for culturing ES cells described above, but DMEM for ES with G418 was used for maintaining and growing MH cells.
- mice Mouse embryos used for chimera production were collected from MCH (Clea Japan) mice. 48 hours after intraperitoneal injection of 7.5 IU intraperitoneally to pregnant mare serum gonadotropin (6 to 8 week old MCH female mice) 7.5 IU was injected intraperitoneally, and the mice were mated overnight with inbred mice.
- Female mice were sacrificed 60 to 64 hours after injection of human chorionic gonadotropin, and 8-cell stage embryos were collected from fallopian tubes by fallopian tube perfusion using M2 medium (Sigma). Drops of DMEM or M16 medium (Sigma) for ES with a 30 // degree were dropped on 60 marauding dishes, and paraffin oil (Nacalai Tesque) was layered on top of it.
- mice embryos in the di Dzushu under conditions of 5% C0 2, 37 ° C , and cultured until required.
- a glass tube (Microcaps25, Dramont) is set in a microelectrode maker (PN-3, NARISHIGE), and the glass tube is pulled.
- the glass tube was manufactured by processing it with sharp tweezers while observing the tip of the glass tube below.
- the pipette for holding embryos is made by heating a glass tube (GDC-1, Narishige) with the flame of a gas burner and pulling it thinly. After confirming that the outer diameter was about 150 mm and the cut end was flat, the inner diameter was about 10 mm using a heating wire, and one part was bent with a small flame of a gas burner.
- the MH cells to be used for chimera production were treated with 0.25% trypsin (Gibco), collected by centrifugation at 1000 rpm for 5 minutes, and suspended in DMEM for ES. About 30/1 of this cell suspension was dropped on a 100-cell dish (coning) and layered with paraffin oil (Nacalai Tesque). This was mixed with a micromanipulator (MMW-202, MMW- 204, Narishige) was mounted on an inverted microscope (TMD, Nikon) stage. A microinjector (IM-5, Narishige) filled with sterilized distilled water was fitted with a glass pipet for holding mouse embryos, and cells were placed in a microinjector (IM-6, Narishige) filled with air.
- IM-5, Narishige sterilized distilled water
- a glass pipette for injection was attached.
- the MH cell suspension spot was placed in the center of the field of view of the inverted microscope, and a glass pipette for cell injection was inserted into the spot to aspirate the MH cells.
- 20 to 30 mouse 8-cell stage embryos that had been cultured were transferred to spots using Pasteur bits.
- the mouse embryo was retained with the embryo-retaining pit and focused on the embryo, the injection pit was manipulated to penetrate the transparent body, and 10 to 15 cells were injected into the perivitelline space.
- the embryos obtained by repeating the above procedure are placed as droplets on the aforementioned 60-band dish, transferred to DMEM or M16 media for ES with paraffin oil overlaid, and transformed into blastocyst stage embryos.
- the cells were cultured until they emerged, and were transplanted the next day.
- MCH female mice (CLEA Japan) of 8 weeks or older were allowed to live and mate overnight with syngeneic osseous mice ligated with vas deferens, and those whose vaginal plugs were confirmed the next day were used as pseudopregnant female mice as pseudo-pregnant female mice.
- the day after mating was designated as first pregnancy, mice on the fourth day of pregnancy were subjected to embryo transfer.
- For anesthesia use tribromoethylamine (Aldrich) with amyl alcohol. (Aldrich), and diluted with physiological saline to a concentration of 2.5%. Avatin was anesthetized by intraperitoneal injection according to the weight of the mouse.
- the integument was cut along the spine, scissors were inserted between the muscle layer and the integument, and both were exfoliated.
- the muscle layer covering the ovaries was incised, the adipose tissue was pinched with forceps, and the ovaries, fallopian tubes, and the upper part of the uterine horn were pulled out onto sterile filter paper.
- the transplantation pit was heated at a gas burner to bend one place, and the inner pulp was processed to be slightly larger than one embryo.
- DMEM for ES or M2 medium
- Inhalation uses the capillary phenomenon to inhale the DMEM medium for ES, and then injects air to create one or two small air bubbles in the pipe, and then leaves about ten embryos to be transplanted at intervals. Inhalation was carried out together with the DMEM medium for ES, and at the end, a small air bubble was inserted and the tip was filled with a small amount of DMEM medium for ES.
- the foster mother gave birth 16 to 17 days after embryo transfer and was nursed 3 weeks after birth until weaning.
- the foster mothers who could not deliver normally despite confirmation of pregnancy, they were cesarean-sectioned within one day after the birth schedule and the offspring were removed and reared to lactating female mice as foster children.
- the offspring weaned 3 weeks after birth were separated into cages by gender, and holes were punched in the ears for individual identification.
- the tail of the mouse was cut by about 1 to 1.5 cm, and further cut with surgical scissors.
- the sample was transferred to a 15-ml tube, and genomic DNA was extracted using a Puregene DNA Isolation Kit (Gentra System), and PCR was performed using this as a ⁇ type.
- CYP3A4 By performing PCR using primers prepared for the purpose of detecting CYP3A family one gene (CYP3A4, CYP3A5, CYP3A7), a mouse individual having human chromosome 7 containing these CYP3A family one gene was identified. .
- the primer sequences used were SEQ ID Nos. 1 and 2
- the primer sequences used to detect CYP3A5 were SEQ ID Nos. 3 and 4
- the primer sequences used to detect CYP3A7 used were SEQ ID Nos. 5 and 6.
- PCR reaction solution was lO x Ex Taq Buffer (Takara Shuzo) 3 ⁇ 1, dNTP (dATP, dGTP, dCTP and dTTP, 2.5mM each) (Takara Shuzo) 4.81, each primer 10pmol, 100ng genomic DNA, Ex Taq (5U / ml) (Takara Shuzo) 0.5 l was added to sterile distilled water to make a total of 30 l, and dispensed into PCR tubes (PerkinElmer). All operations in the process of preparing the PCR reaction solution were performed on ice.
- thermocycler GeneAmp PCR system 2400, Perkin Elmer
- the thermocycler was set at 85 ° C, and after confirming that the temperature reached 85 ° C, the tube was set.
- a mouse individual in which any of the above three human CYP3A family genes was detected was confirmed. These mice were considered to be chimeric mice harboring a human chromosome 7 fragment containing the CYP3A family gene.
- Example 4 Assay for Expression of CYP3A4 Gene in Chimeric Mouse Carrying Human Chromosome 7 Fragment Containing CYP3A Family Gene
- human chromosome 7 fragment containing the CYP3A family gene was analyzed by PCR.
- RT-PCR analysis was performed on individuals considered to be possessed chimeric mice (hereinafter abbreviated as "chimeric mice") to confirm whether the introduced CYP3A4 gene was expressed at the individual level.
- mice that extract RNA were set as shown in Table 2. did.
- the dosing solution was prepared by suspending rifampicin in corn oil (Sigma). The single dose was 100 mg / kg.
- Table 2 Sample treatment method Chimeric mouse Rifampicin 100 mg / kg intraperitoneally for 4 days
- MCH mouse vehicle (corn oil) administered intraperitoneally for 4 days
- cDNA was synthesized from a part of the RNA solution of various organs.
- RNA in order to remove genomic DNA contaminating the RNA solution, put 1.5 to 5 g of RNA, 1 to 1 DNasel (Gibco), 1 to 1 lO x DNase l reaction on buffer (Gibco) in a 1.5 ml tube, The total volume was adjusted to 101 with RNase free water, and incubated at room temperature for 15 minutes to perform treatment with DNase. The reaction was terminated by adding 25 mM EDTA 1/1 to stop the reaction of DNase, and further incubated at 65 ° C for 10 minutes.
- cDNA synthesis was performed using the Super Script TM Preamplification System (Gibco). Randam hexamers (Gibco) was added to the above-described DNase-treated RNA solution, incubated at 70 ° C for 10 minutes, and then transferred to ice. To this tube, add 10X PCR buffer (GIBCO) 2 ⁇ 1, 25mM MgC 2 ⁇ 1, dNTP (dATP, dGTP, dCTP and dTTP, 10mM each) l ⁇ l, 0.1M DTT 2 / z 1 It was added, mixed gently, and incubated at 25 ° C for 5 minutes.
- Gibco Super Script TM Preamplification System
- Antisense 5'-TCTGAGCGTTTCATTCACCA-3 5 (SEQ ID NO: 8)
- PCR reaction solution is lO x Ex Taq Buffer (Takara Shuzo) 3 ⁇ 1, dNTP (dATP, dGTP, dCTP and dTTP, 2.5mM each) (Takara Shuzo) 4.8 / 1, each primer 10pmol, Genome DM lOOng, Ex Taq ( 5U / ml) (Takara Shuzo) 0.5 ⁇ 1 was added to sterile distilled water to make a total of 30 ⁇ 1 and dispensed into PCR tubes (PerkinElmer). All operations in the process of preparing the PCR reaction solution were performed on ice.
- the thermal cycler (GeneAmp PCR system 2400, Perkin Elmer) was set at 94 ° C, and after confirming that the temperature reached 94 ° C, the tube was set. After pre-PCR at 94 ° C for 5 minutes, the reaction was performed for 35 cycles with 1 cycle at 94 ° C for 30 seconds, 60 ° C for 1 minute, and 72 ° C for 1 minute, followed by treatment at 72 ° C for 15 minutes. . Electrophoresis was performed on a liver sample of each mouse, and the presence or absence of CYP3A4 expression was examined. As a result, CYP3A4 expression was observed in the liver of chimeric mice to which rifampicin was administered.
- 2 is the result of EcoRI treatment of the PCR product derived from rifampicin-administered mouse liver
- 3 is the result of EcoRI treatment of the human liver-derived MA PCR product
- 4 is the PCR product derived from rifampicin-administered mouse liver
- 5 is the human liver It is a PCR product of the derived RNA. Further, as a result of analyzing the gene sequence of this PCR product, it was confirmed that the sequence matched a part of the sequence of the human CYP3 A4 gene. When CYP3A4 expression was examined in other organs (Fig. 2), expression of human CYP3A4 gene was observed in the liver (Fig. 2) and small intestine (Fig.
- a 100% chimera in which human CYP3A4, 3A5, and 3A7 were confirmed (individual exhibiting the color of agooch in 100% of the body surface) was used. Since the MH cells used were derived from TT2F, all the 100% chimeric mice exhibited a female phenotype, which was co-located with MCH-type os mice and crossed to obtain offspring. The tails of the 11 litters of the same litter obtained were cut about 1-1.5 cm in length, and further minced with surgical scissors. The sample was transferred to a 15 ml tube, and genomic DNA was extracted using a Puregene DNA Isolation Kit (Gentra System), and PCR was performed using this as a ⁇ type. A TC mouse individual having human chromosome 7 was identified using a primer prepared for the purpose of detecting the CYP3A family gene (CYP3A4, CYP3A5).
- Antisense 5'-TCAGTGAGGCTGTTGGATTG-3 '(SEQ ID NO: 10)
- Antisense 5, -TATCCTCTCACCTGCCCTTG-3, (SEQ ID NO: 12)
- PCR reaction solution is lO x Ex Taq Buffer (Takara Shuzo) 3 ⁇ 1, dNTP (dATP, dGTP, dCTP and dTTP, 2.5mM each) (Takara Shuzo) 4.8 ⁇ 1, each primer 10pmol, genomic DNA lOOng, Ex Taq (5U / ml) (Takara Shuzo) Sterile distilled water was added to 0.5 ⁇ 1 to make a total of 30 ⁇ 1 and dispensed into PCR tubes (PerkinElmer). All operations in the process of preparing the PCR reaction solution were performed on ice.
- a thermal cycler (GeneAmp PCR system 2400, Perkin Elmer) was set at 85 ° C, and after confirming that the temperature reached 85 ° C, the tube was set. After pre-PCR at 85 ° C for 3 minutes, 94 ° C for 1 minute, and 85 ° C for 1 minute, 40 cycles of 94 ° C for 30 seconds, 62 ° C for 45 seconds, and 72 ° C for 1 minute are performed 40 times. After that, treatment was performed at 72 ° C for 20 minutes. As a result, CYP3A4 was detected in 5 individuals, and CYP3A5 was detected in 1 individual.
- BAC library (Kurabo Industries) derived from a mouse (C57BL / 6, 129 / Sv)
- a BAC clone containing Cyp3all, 13, 16 or 25 was isolated by PCR and hybridization.
- Antisense 5, -GCTGACAAACAAGCAGGGAT-3 '(SEQ ID NO: 14
- Antisense 5, -GGAGTGGGTTTTCTGGTTGA-3, (SEQ ID NO: 16
- PCR was performed using Perkin-Elmer GeneAmp 9600 as the thermal cycler, Ex Taq (Takara Shuzo) for Taq polymerase, and Ex Taq (Takara Shuzo) for buffer and dNTP (dATP, dGTP, dCTP and dTTP). The ones attached to were used according to the recommended conditions. Cycling conditions were as follows: heat denaturation at 94 ° C for 1 minute, 35 cycles of 98 ° C for 10 seconds, 65 ° C for 30 seconds, and 72 ° C for 1 minute. , All performed under these conditions).
- BAC DNA was extracted from the above positive BAC clones (clones containing any of Cyp3all, 13, 16, and 25) using an automated plasmid extractor (Kurabo Industries) and spotted on Hybond-N + membrane (Amersham). Then, a dot hybridization was performed using a probe capable of specifically detecting Cyp3all, 13, 16, and 25 (used for screening of the BAC library) (probe preparation, conditions, etc.). Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., 1994). The results are shown in Figure 3 (only representative clones are shown, not all BAC clones).
- the sequences of the T7 promoter and the SP6 promoter are present at both ends of the insert DNA cloning site, and the use of these as primers enables the sequencing of both ends.
- the following primers were designed from the sequence on the SP6 side of clone 679, and PCR was performed on the remaining BAC clones.
- BAC clone 741 contains only 3al6 and has 3aY at its end, suggesting that it is present on the chromosome in the order of Zfp-3aY-3al6--3al1_3a25, with 3aY being one end of the cluster. It was considered. Furthermore, BAC clone 740 was sequenced by T7 primer (consigned to Toray Research Center), and a homology search was performed. As a result, it was highly homologous to the rat Cyp3A gene and only weakly homologous to 3al3 in mice. It was found that there was a sequence exhibiting sex.
- Cyp3aX This also suggests the existence of a further novel Cyp3a gene, and we will call it Cyp3aX.
- BAC clone 740 contains only 3al6 and has 3aX at its end, suggesting that it exists on the chromosome in the order of Zfp-3aY-3al6- 3aX-3al-1-3a25.
- terminal sequencing was performed on the BAC clone 9736 containing 3a25 using T7 primer and SP6 primer (Toray Research, Inc.). (Consigned to Sen Yuichi). The following STS primer was designed based on this sequence.
- Antisense 5'-TTTCTGGATGTCACTGGTCC-3 '(SEQ ID NO: 26) Using this primer, PCR was performed on a BAC clone at hand (a BAC clone containing any of Cyp3all, 13, 16, 16, and 25). Since it was found that the T7 side was located outside the class, we screened the mouse BAC library further with this primer. As a result, clone 29H12 was obtained. Similarly, end sequencing was carried out, and the following STS primer was designed.
- BAC clones containing any of 13, 16, and 25 and BAC clones adjacent to them were hybridized under mild conditions.
- the cDNA probe was prepared by performing PCR using the Mouse Primer QUICK-Clone cDNA (Clonetech) as a template with the following primers.
- BAC clones containing Cyp3al3 were not linked to any of the BAC clones containing Cyp3all, 16, and 25 in the above screening range. Therefore, chromosome walking was performed as described above using clone 703 as a starting material. First, we performed the terminal sequence of clone 703 (consigned to Kenichi Research Center) and designed the following primers.
- Antisense 5, -GGGTTGTTGGACTCACAGAGAG-3 '(SEQ ID NO: 32) (T7 primer for clone 703)
- Antisense 5'-ATGGTGCTCAGCAATAGTAGGG-3 '(SEQ ID NO: 34)
- Antisense 5, -AAACCCCTTAAACCCACAGC-3, (SEQ ID NO: 36)
- BAC clone at hand (BAC clone containing any of Cyp3all, 13, 16, 16 and 25 and BAC adjacent to them)
- BAC clone As a result of performing PCR on the (clone), it was found that the SP6 side was located on the outside. Therefore, further BAC library screening was performed using this primer, and clones 130A11 and 29B19 were obtained. These clones were subjected to end sequencing, and the following primers were designed.
- Antisense 5'-TGTGTGTGGGTTGGTGTCTC-3 '(SEQ ID NO: 46) Using these primers, a BAC clone at hand (a BAC clone containing any of Cyp3all, 13, 16, and 25 and a BAC clone adjacent to them) ), PCR was performed. As a result, it was found that the T7 side of clone 29B19 was located outside. Therefore, further BAC library screening was performed with this primer to obtain clones 204B19 and 173D23. These clones were subjected to the terminal sequence (consigned to Toray Research Center), and the following primers were designed.
- Antisense 5, -CCAGGTTATCGCTGGTCTTC-3, (SEQ ID NO: 48) This primer was used to obtain a BAC clone at hand (a BAC clone containing any of Cyp3all, 13, 16, 25 and a BAC clone adjacent to them). As a result of PCR, it was found that the SP6 side of clone 173D23 was located outside.
- Antisense 5'-CGGGAAGTATTGCTTTCAGC-3 '(SEQ ID NO: 50)
- Antisense 5'-GAGTGGGCTCTGGTCATTTC-3 5 (SEQ ID NO: 52) Using these primers, PCR was performed on the BAC clone at hand (the BAC clone containing any of Cyp3all, 13, 16, and 25 and the BAC clone adjacent to them). Since the side was found to be located on the outside, further screening of the BAC library was performed with this primer to obtain clone 204L9. The terminal sequence of this clone (consigned to Toray Research Center) was performed, and the following primers were designed.
- BAC clones obtained (contigs of BAC clones containing 3al3) were relaxed using a cDNA probe near the full length of 3a25 as described above. A hybridization was performed. As a result, clones that became positive were 703, 503, 705, 9743, 220H2, 234H9, and 130A11, and BAC clones 29B19, 204B19, 173D23, 9667, 86H16, and 204L9 located further outside were negative. .
- FIG. 3 summarizes the above experimental results.
- the red BAC clone is a clone that was positive with a cDNA probe near the full length of 3a25, and the black BAC clone is a clone that was negative.
- Example 7 Mouse Cy 3a 3 ⁇ 4yunko class Yuichi 3aY-3al6- 3aX-3al1-3a25 Of a targeting vector
- the cassette vectors ploxPUP and ploxPDOWN for inserting ⁇ at both ends of the Cyp3a gene cluster were prepared as follows. First, the preparation of ploxPUP is described. Plasmid pBluescript IISK (-) (Toyobo) restriction enzyme EcoRV
- the digested end was dephosphorylated using a phosphatase CIAP (alkaline phosphatase from calf small intestine, Takara Shuzo) at 50 ° C for 30 minutes.
- a DNA fragment cut out from plasmid pBS302 (Gibco) with restriction enzymes Spel and Hindlll (Boehringer I) and blunt-ended with DNA Blunting kit (Takara Shuzo) was added to the DNA fragment.
- Ligation was performed using Ligation kit (Takara Shuzo) and transformed into competent cell DH5 (Toyobo) of Escherichia coli (plasmid PBS302HS). The blunt-end, ligation and transformation were performed according to the protocol attached to each kit.
- Plasmid PBS302HS was added to Plasmid PBS302HS.
- Plasmid PBS302HS was cloned using the DNA Ligation kit (Takara Shuzo) into the Smal site (dephosphorylated in the same manner as described above) to obtain plasmid ploxPneo.
- Blasmid pMClDT-A (Gibco) was digested with restriction enzyme Apal (Beiling Ringer), blunted, and dephosphorylated, and phosphorylated Notl linker (Takara Shuzo) was inserted to obtain plasmid pMClDT-AN. .
- the Fsel linker is added to the Sac1 site of the plasmid p Bluescript IIS (-) (Toyobo) as described above. Inserted.
- the Fsel linker synthesized the oligo DM having the following sequence and phosphorylated the 5 'end (consigned to Glyna).
- the Spel linker (Takara Shuzo) was inserted into the Clal site of the brassmid pGREEN LANTERN-1 (Gibco) as described above, and a DNA fragment cut out of this plasmid with the restriction enzyme Spel (Boehringer) was used to convert it into Spel. After cleavage with, the plasmid was cloned into the dephosphorylated plasmid ploxPDT-A. Finally, this plasmid was digested with the restriction enzyme Smal (Boehringer), dephosphorylated, cut out from the brassmid pGKPuro with the restriction enzyme Sail (Beiling Ringer), and the blunted DNA fragment was cloned (plasmid). ploxPDOWN).
- FIG. 4 shows the structure of the cassette vectors ploxPUP and ploxPDOWN constructed as described above.
- BAC clone 741 Plaque hybridization was performed using the T7-terminal probe of this Example to obtain a recombinant phage containing a 13 kb DNA fragment of the T7-terminal region of BAC clone 741. The resulting phage is called the clone UP.
- the T7-terminal probe of BAC clone 741 was carried out using the following oligo DNA (synthesizing was outsourced to GRINA).
- Hybridization is performed in 6 x SSC, 0.53 ⁇ 4 SDS, 5 x Denhardt at 57 ° C, overnight, and washing is performed in 2 X SSC, 0 Performed at 65 ° C. in 5% SDS.
- the inserted DNA fragment was subjected to a sequence with primer M13-20 (Toray Research Center), and it was found that the inserted DNA fragment was located at the SP6 end of the phage vector.
- the following primers were designed from this sequence. (Primer for clone D0WN12 SP6 side)
- Antisense 5'-CACACACGTCTTTTTGGCAG-3 '(SEQ ID NO: 57) Using this primer, PCR was performed on BAC clones 29H12 and 41012, and only 29H12 was positive. I knew that they were in a positional relationship.
- the phage LUP and plasmid pDOWN were used as clones corresponding to both terminal genomic regions of the Cyp3a gene cluster for the preparation of the evening-getting vector described below.
- the plasmid was cut with restriction enzyme Xhol (Boehringer), blunt-ended, and Kpnl linker (Takara Shuzo) was inserted.
- This plasmid is cleaved with restriction enzymes Not I and Xba I (Boehringer), and the restriction enzymes Not I and SpeI are converted from plasmid pMClDT-AN.
- the construction of the evening getter vector ploxP3aD0WN is described.
- the plasmid pDOWN was cut with the restriction enzyme EcoRI (Boehringer), blunt-ended, and inserted into Sail linker (Takara Shuzo). This plasmid is converted to the restriction enzymes Notl and Spel (Berry The DNA fragment cut from the plasmid pMClDT-AN with the restriction enzymes NotI and Spel (Beringer) was cloned.
- this plasmid was digested with restriction enzyme Not I (Behringer), blunt-ended, and Srfl linker was inserted.
- the Srfl linker used the following synthetic oligo DNA (Grainer-1).
- the ⁇ sequence was inserted into both ends of the Cyp3a gene cluster using the two evening vector vectors ploxP3aUP and ploxP3aD0WN shown in the above Examples.
- the Yuichiichi targeting vector ploxP3 aUP was linearized with the restriction enzyme Notl (Takara Shuzo), and the mouse ES cell TT2F was transformed according to the conventional method (Shinichi Aizawa, Biomanual Series 8, Gene Evening, Yodosha, 1995). Introduced.
- TT2F cells were treated with trypsin, suspended in cold HBS (HEPES-buffered saline) at 2.5 ⁇ 10 7 cells / ml, and then added with 45 jug of Vector-1 and Gene Pulser (BioRad). Electrification at 250 V, 960 ° F was performed using an election port. Electorate-porated cells are suspended in 8 ml of ES medium (Shinichi Aizawa, Bio Manual Series 8, Gene Yuichi Getting, Yodosha, 1995) and seeded on eight 60 mm dishes pre-soaked with feeder cells did. Culture for 48 hours, and then culture containing G418 (GIBC0) 300 g / ml (apparent concentration).
- G418 GIBC0
- the cells were selectively cultured in the ground for about 10 days.
- the resulting 144 G418-resistant colonies were picked up, cultured in a 48-well plate until confluent, and cells of one well of a 48-well plate were seeded on two wells of a 4-well plate.
- One well of a 4-well plate was stored frozen at -80 ° C. The remaining one well was seeded and cultured on a 3.5 cm gelatin-coated dish for obtaining genomic DNA.
- Other specific procedures for handling mouse ES cells followed the methods described in W097 / 07671 and W098 / 37757.
- Genomic DNA was extracted by the phenol method.
- the extracted genomic DNA was digested with a restriction enzyme Hind lll (NEB), separated by agarose gel electrophoresis, and then homologous recombinants (referred to as ES / loxP3aUP) were identified by Southern hybridization.
- a DNA fragment (about 400 base pairs) of the mouse Cyp3aY region was used as a probe for Southern plotting to detect a clone in which homologous recombination occurred with the evening-getting vector ploxP3aUP.
- This DNA fragment was obtained by PCR amplification of C57BL / 6 mouse DNA as type III under the following conditions.
- Antisense 5, -TCCATGACAATAAGGCTGCC-3, (SEQ ID NO: 59)
- PCR For PCR, use GeneAmp9600 manufactured by Perkin-Elmer as a thermal cycler, use LA Taq (Takara Shuzo) for Taq polymerase, and attach buffers and dNTPs (dATP, dCTP, dGTP, dTTP) as recommended. Used according to. The temperature and cycle conditions were as follows: heat denaturation at 85 ° C for 3 minutes and 94 ° C for 1 minute, and then 35 cycles of 98 ° C for 10 seconds, 65 ° C for 30 seconds, and 72 ° C for 1 minute.
- the mouse ES cell TT2F was introduced by electoral portation.
- the cells were cultured in a normal ES medium (Shinichi Aizawa, Biomanual Series 8, Gene Yuichi Getting, Yodosha, 1995) for 24 hours, and then G418 (Gibco) 300 ⁇ g / ml ( The cells were selectively cultured in a medium containing (apparent concentration) for about one week. The resulting 392 G418-resistant colonies were picked up, cultured until they became confluent on a 24-well plate on which feeder cells had been seeded, and then seeded on a 12-well plate on which feeder cells had been seeded.
- Genomic DNA was extracted using Puregene DNA Isolation Kit (Gentra System). The extracted genomic DNA was digested with a restriction enzyme Hindl II (Boehringer), separated by agarose gel electrophoresis, and homologous recombinants (referred to as ES / loxP3aUP) were identified by Southern hybridization. The same probe as in (1) was used as the probe for Southern blotting to detect a clone in which homologous recombination occurred with the evening targeting vector ploxP3aUP.
- Hindl II Boehringer
- Homologous recombinants were detected by Southern blot analysis using the above-mentioned probe (Amersham Megaprime DNA Labeling System was used for labeling the probe). As a result, 2 out of 392 clones were homologous recombinants. In wild-type TT 2F cells, a band was confirmed at about 10 kb by Hindlll digestion. This band disappeared in the homologous recombinant, and a band was newly detected at a position of about 5 kb (see FIG. 6). This confirmed that the loxP sequence was inserted into the target site by homologous recombination.
- Example 9 Production of chimeric mice from homologous recombinant ES cells (ES / loxP3aUP)
- ES / loxP3aUP A chimeric mouse using ES cells having a human chromosome 7 fragment containing the CYP3A family gene shown in Example 3 using the homologous recombinant TT2F cell line (ES / loxP3aUP) obtained in Example 8 (2).
- a chimeric mouse was prepared in the same manner as described above. That is, two clones of ES / loxP3aUP, 115 and 305, obtained in Example 8 (2) were MCH (ICR) (CLEA Japan). 10-20 injections per injection.
- ES cell medium W097 / 07671
- pseudo-pregnancy treatment 2.5 days after injection into the uterus of the foster parent ICR mouse, about 10 cells per uterus Embryos were implanted.
- 855 injected embryos were transplanted into the uterus of foster mother mice to obtain 29 chimeric mice, and the contribution of ES / loxP3 aUP to somatic cells (chimera rate) was 100%. Close individuals were obtained.
- 429 fusion embryos were transplanted into the uterus of the foster mother mouse to obtain one chimeric mouse.
- Example 10 Acquisition of Cell Lines in which ⁇ Sequences were Inserted at Both Ends of Mouse ES Cell Cy P 3a Gene Cluster
- electoral poration was carried out in the same manner as in Example 8 using the evening targeting vector ploxP3aD0WN.
- the evening targeting vector — ploxP3aD0WN was linearized with the restriction enzyme Srf1 (Toyobo), and the mouse ES was purified according to the conventional method (Shinichi Aizawa, Bio Manual Series 8, Gene Yuichi Getting, Yodosha, 1995).
- the cells were introduced into TT2F.
- TT2F cells were treated with trypsin, suspended in HBS (HEPES-buffered sine) to a concentration of 2.5 ⁇ 10 7 cells / ml, and then added with 15 ⁇ g of Bec Using a pulsar (biorad), electoral porting was performed under the conditions of 250V and 960F.
- Genomic DNA was extracted from the puromycin-resistant clone in the same manner as in Example 8, and a homologous recombinant (ES / loxP3a UP + D0WN) was identified by Southern hybridization.
- Genomic DNA was extracted using a Puregene DNA Isolation Kit (Gentra System).
- the extracted genomic DM was digested with restriction enzymes Xhol I XbaK and Xhol / EcoRI (Behringer), separated by agarose gel electrophoresis, and homologous recombinant (ES / loxP3aUP + D0WN) was isolated by Southern hybridization. ) was identified.
- a DNA fragment (about 700 bases) encoding GFP inside the evening vector vector ploxP3aDOWN as a probe for Southern blotting to detect a clone in which homologous recombination occurred with the evening vector vector ploxP3aD0WN. Pair) was used. This DNA fragment was obtained by cutting out the plasmid pGreen Lantern (Gibco) with the restriction enzyme Notl (Behringer).
- Homologous recombinants were detected by Southern blot analysis using the above-mentioned probe (Amersham Megaprime DNA Labeling System was used for labeling the probe). As a result, 3 out of 348 clones were homologous recombinants. Wild-type TT2F cells did not have a GFP sequence, and thus no band hybridizing with this probe was observed. In the homologous recombinant, a band was detected at about 9 kb by XhoI / Xbal digestion, and a band was detected at about 7 kb by XhoI / EcoRI digestion (see FIG. 7).
- Example 11 Production of chimeric mice from homologous recombinant ES cells (ES / loxP3aUP + D0WN) To confirm whether the homologous recombinant TT2F cell line (ES / loxP3aUP + D0WN) obtained in Example 10 actually retains the ability to form a chimera, the homologous recombinant TT2F cell line (ES / 1oxP3aUP) was used. + D0WN) in the same manner as in Example 9.
- 124 clones 442 injection embryos were implanted into the uterus of a foster mother mouse to obtain eight chimeric mice, and the contribution of ES oxP3aUP + D0WN to somatic cells (chimera ratio) reached 100%. Close individuals were obtained.
- 479 and 204 fusion embryos were transplanted into the uterus of the foster mother mouse, and three chimeric mice each were obtained.
- 124 clones were judged to be superior in the ability to form chimeras to other clones from the viewpoint of the chimera production efficiency and the chimera rate, and were subjected to the subsequent experiments.
- Example 1 (2) Acquisition of mouse ES cell Cyp3a gene cluster-deficient cell line ES cell line ES / loxP3alIP + D0WN obtained by the above two targeting experiments (insertion of ⁇ sequence at both ends of mouse cyp3a gene cluster 1) Among them, 124 clones having a high chimera-forming ability were transfected with pBSl85 (Gibco) expressing Cre recombinase. As a result, site-specific recombination occurred between the ⁇ sequences at both ends of the mouse endogenous cyp3a gene cluster, and as a result, the Cy P 3a gene cluster could be expected to be deleted. The basic procedure was performed according to Example 8 above.
- the ES cell line ES / loxP3aUP + D0WN is treated with trypsin, suspended in HBS at l.O x lO 7 cells / ml, 30 ⁇ g of pBS185 vector is added, and the mixture is added using a Gene Pulser. Electrification was carried out under the same conditions as in Example 8 above. Then 100 marshals Les Seeded on one sheet. When recombination occurred as expected, the GFP (Green Fluorescent Protein) gene in the vector was expressed, and it was considered detectable by fluorescence emission. From this, after culturing for 72 hours, a GFP-positive cell population was separated by FACS (fluorescence-activated Celso overnight).
- FACS fluorescence-activated Celso overnight
- GFP-positive cells Separation of GFP-positive cells by FACS was performed according to the following procedure. After 72 hours of culture from the introduction of Cre expression vector pBS185, the cells were detached from the dish by trypsinization, suspended in DMEM for ES, transferred to a 15 ml tube, centrifuged at 1000 rpm for 5 minutes, and the supernatant was aspirated. . After tapping the tube, the cells were resuspended in 10 ml of DMEM for ES, seeded on a gelatin-coated 100 mm dish, and cultured for about 1 hour. Thereafter, the medium was gently recovered and centrifuged at 1000 rpm for 5 minutes.
- GFP-2 5'-TGAAGGTAGTGACCAGTGTTGG-3 '(SEQ ID NO: 61)
- PCR reaction solution is lO x Ex Taq Buffer (Takara Shuzo) 3 ⁇ 1, dNTP (dATP, dGTP, dCTP and dTTP, 2.5 mM each) (Takara Shuzo) 4.8 1, 10 pmol of each primer, about 100 ng of genomic DNA, Ex Taq ( 5U / ml) (Takara Shuzo) Sterile distilled water was added to 0.3 ⁇ 1 to make a total of 30 ⁇ 1 and dispensed into PCR tubes (PerkinElmer). All operations in the process of preparing the PCR reaction solution were performed on ice.
- Example 13 Preparation of Chimeric Mouse from Recombinant ES Cell (ES / A3a) Using Recombinant TT2F Cell Line (ES / A3a) C6 Clone Clone An experiment for producing a chimera was performed.
- MCH ICR
- ES / A3a per embryo 10-20 ES / A3a per embryo were injected into 8-cell embryos obtained by mating male and female mice. After culturing overnight in DMEM for ES to generate blastocysts, about 10 indication embryos were transferred to the uterus of the foster mother MCH mouse 2.5 days after the pseudopregnancy treatment. 330 injection embryos were implanted to obtain 10 chimeric mice.
- PCR reaction solution lOxEx Taq Buffer (Takara Shuzo) 3 ⁇ 1, dNTP (dATP, dGTP, dCTP and dTTP, 2.5 mM each) (Takara Shuzo) 4.8 ⁇ 1, each primer 10 pmol, genomic DNA about 100 ng, Ex Taq (5U / ml) (Takara Shuzo) Sterile distilled water was added to 0.3 ⁇ 1 to make a total of 30/1 and dispensed into PCR tubes (PerkinElmer). All operations in the process of preparing the PCR reaction solution were performed on ice.
- the thermal cycler (GeneAmp PCR system 2400, Parkin Elmer) was set at 85 ° C, and after confirming that the temperature reached 85 ° C, the tube was set. After pre-PCR at 85 ° C for 3 minutes and 94 ° C for 1 minute, 30 cycles of reaction were performed with 98 ° C for 10 seconds, 59 ° C for 30 seconds, and 72 ° C for 30 seconds as one cycle. This resulted in three chimeric mice A band of about 200 base pairs was detected in all of the mice, confirming that the mouse was a knockout mouse lacking the Cyp3a gene cluster.
- mice bearing approximately 10 8 human chromosome 7 Microcells were purified from A9 cells H5 and suspended in 5 ml of DMEM. After 2 washes the L ⁇ 2xl0 7 amino Niwatori DT40 cells DMEM, suspended in DMEM 5 ml, was added to the centrifuged microcells, and centrifuged 10 minutes at 1500 rpm, completely remove the supernatant. The precipitate was sufficiently loosened by tapping, 0.5 ml of PEG 1500 solution (Boehringer) was added, and the mixture was sufficiently stirred for about 2 minutes.
- DMEM 10 ml Oyutsuku Rikuwae, centrifuged for 10 minutes at 1500 rpm, 10% ⁇ Shi fetal serum (Gibco, referred below FBS), 1% D Wa tri serum (Gibco), 10- 4 M 2-
- the cells were cultured in RPMI1640 medium (Gibco) supplemented with mercaptoethanol (Sigma) (hereinafter abbreviated as “DT40 medium”). After 24 hours, the medium was replaced with a medium containing 1 mg / ml G418 (hereinafter abbreviated as G418-DT40 medium), and selective culture was performed for about 3 weeks.
- G418-DT40 medium a medium containing 1 mg / ml G418
- Antisense 5'-CCTAAAGGAAACGAACAGCG-3 '(SEQ ID NO: 63)
- PCR For PCR, use GeneAmp9600 manufactured by Perkin-Elmer as a thermal cycler, Ex Taq (Takara Shuzo) for Taq polymerase, and use the attached buffer and dNTP (dATP, dCTP, dGTP, dTTP) as recommended conditions. Used according to The temperature and cycle conditions were as follows: heat denaturation at 94 ° C for 1 minute, followed by 35 cycles of 98 ° C for 10 seconds, 56 ° C for 30 seconds, and 72 ° C for 30 seconds. As a result, out of about 30 clones, 2 clones were positive for CYP3A4 and MDR1.
- Example 15 Preparation of 5 cassette vectors ploxPHyg and ploxPbsr Force vectors ploxPHyg and ploxPbsr for inserting the ⁇ sequence which is a recognition sequence of Cre recombinase on human chromosome were prepared as follows. As described above, PGK promoter should be transcribed in the former cassette vector and PGK promoter should be transcribed in the latter to enable positive selection of cells in which translocations occur as expected. It was constructed to include the GFP gene.
- Plasmid pBluescript II SK (-) (Toyobo) is cut with the restriction enzyme EcoRV (Boehringer), and the phosphatase CIAP (alkaline phosphatase derived from calf small intestine, Takara Shuzo) is used at 30 ° C. After the reaction, the cut ends were dephosphorylated.
- EcoRV EcoRV
- phosphatase CIAP alkaline phosphatase derived from calf small intestine, Takara Shuzo
- DNA fragment excised from plasmid PBS302 (Gibco) with restriction enzymes Spel and Hindll (Boehringer) and blunt-ended with DNA Blunting kit (Takara Shuzo) was ligated using DNA Ligation kit (Takara Shuzo), Escherichia coli cell DH5 (Toyobo) was transformed (Brassmid PBS302HS). Blunting, ligation and transformation were performed according to the protocol attached to each kit.
- this plasmid PBS302HS is cleaved with the restriction enzyme Sail (Beilinger), dephosphorylated, and then digested with the restriction enzyme pGKPuro (supplied from WHITEHEAD INSTI TUTE, Dr. Peter W. Laird).
- the PGK promoter overnight fragment cut out with Sail and Xhol (Beilinger) was cloned to obtain plasmid PBSPGK302HS.
- This plasmid was digested with restriction enzymes EcoRI and Notl (Boehringer), blunted and dephosphorylated, and Notl linker (Takara Shuzo) was ligated (plasmid PBSPGK302HSN).
- the hygromycin B resistance gene cassette was cut out by cutting Blasmid # 1-133 (provided by Prof. Shunichi Takeda of Kyoto University School of Medicine) with the restriction enzyme BamHI (Beilinger), and the ends were blunted. Plasmid PBSPGK302HSN was digested with restriction enzyme SaIII (Boehringer) and blunt-ended. After that, a hygromycin B resistance gene cassette was cloned (plasmid ploxPHyg).
- Plasmid pGREEN LANTERN-1 Inserts Spel linker (Takara Shuzo) into Clal site as described above and cuts it out with restriction enzyme Spel (Boehringer) to cut GFP gene cassette fragment with Spel after, and cloned into Burasumi de P BSSfK302B dephosphorylated (pBSSfK302BGFP).
- This plasmid is cut with the restriction enzyme Xbal (Boehringer), blunt-ended, and then cut out from Plasmid # 1-134 (provided by Professor Shunichi Takeda, Kyoto University School of Medicine) with the restriction enzyme BamHI (Beiling Ringer) to make it blunt-ended.
- FIG. 16 The obtained DNA fragment (blasticidin S resistance gene cassette) was cloned (ploxPbsr).
- Figure 8 shows the structures of cassette vectors ploxPHyg and ploxPbsr.
- Example 16 6 Preparation of Targeting Vectors PBSC0L1A21OX (F) and PBSC0L1A21OX (R)
- the targeting vectors pBSC0LlA21ox (F) and pBSC0LlA21ox (R) for inserting the ⁇ sequence were prepared as follows. Since it is unclear whether the direction of transcription of C0L1A2 is centromeric or telomere centromeric, two-way targeting vectors (F) and (R) were prepared.
- the C0L1A2 genomic region was amplified by using the DT40- # 7 genomic DNA obtained in Example 14 above as a template using the following primers. At this time, a recognition site for the restriction enzyme Kpnl was added to the 5 'end of the primer so that the PCR product to be amplified could be cloned into the vector. (Breamer for amplification of C0L1A2 gene region)
- PCR used GeneAmp2400 manufactured by Perkin-Elmer as thermal cycler, LA Taq (Takara Shuzo) for Taq polymerase, and used the buffer and dNTP (dATP, dCTP, dGTP, dTTP) according to the recommended conditions. .
- the temperature and cycle conditions were as follows: heat denaturation at 94 ° C for 1 minute, and 35 cycles of 98 ° C for 10 seconds and 65 ° C for 15 minutes.
- the PCR product was treated twice with phenol-form and then gel-filtrated with CHROMA SPIN-TE400.
- the cells were cut with a restriction enzyme Kpnl (Roche Diagnostics), treated twice with phenol-cloth form, and then subjected to gel filtration with CHROMA SPIN-TE1000 (Clontech).
- Kpnl a restriction enzyme
- CHROMA SPIN-TE1000 a restriction enzyme that causes gel filtration.
- the plasmid was deleted by blunting and self-ligation, and the plasmid vector pS ( N) Sr].
- the oligo DNA having the following sequence was used for the Srfl linker.
- the PCR fragment of the C0L1A2 gene having the above Kpnl end was cloned into the Kpnl site of -pGCCCGGGC-3 'plasmid [pBS (N) Sr] to prepare a plasmid PBSC0L1A2.
- This plasmid was digested with the restriction enzyme Stul (Roche Diagnostics), dephosphorylated, and Notl linker-(Takara Shuzo) was inserted to prepare pBSC0LlA2Not.
- the human telomere sequence was synthesized by PCR according to JJ Harrington et al. (Nature Gnet., 15, 345-355, 1997) and cloned into the EcoRV site of plasmid pBlues cript IIS (-) (Toyobo) (pTEL).
- the EcoRI site of the plasmid pGKPuro available from WHITEHEAD INSTITUTE, Dr. Peter W. Lai rd
- was changed to a Notl site and a DNA fragment (pure mycin resistance gene cassette) cut out with the restriction enzyme Notl (Boehringer).
- Notl pure mycin resistance gene cassette
- the genomic region of the AF006752 locus was amplified by PCR using the DT40- # 7 genomic DNA obtained in Example 14 above as a type III and the following primers.
- a recognition site for the restriction enzyme BamHI was added to the 5 'end of the sense primer so that the amplified PCR product could be cloned into a vector.
- PCR For PCR, use GeneAmp2400 manufactured by Perkin-Elmer as a thermal cycler, use LA Taq (Takara Shuzo) for Taq polymerase, and attach buffers and dNTPs (dATP, dCTP, dGTP, dTTP) as recommended. Used according to Temperature and cycle conditions are 94 ° C 1 After heat denaturation for one minute, 35 cycles were performed with 98 ° C for 10 seconds and 65 ° C for 15 minutes as one cycle. The obtained PCR product of about 8 kb was treated twice with phenol / cloth form, and then subjected to gel filtration with CHROMA SP IN-TE1000 (Clontech).
- the cloned AF006752 genomic fragment of 5.3 kb was designated as (F) when it was in the same direction as the human telomere sequence and (R) when it was in the opposite direction [pTELPuro5.3 (F), (R), Fig. 11] .
- Example 19 Site-Specific Cleavage of Human Chromosome 7 in Chick DT40 Cells
- the targeting vector pTELPuro5.3 (F) prepared in Example 18 above was substituted for DT40- # 7 obtained in Example 14 above. , (R), and attempted to cut chromosome 7 at the insertion site by inserting a human telomeric sequence into the AF006752 genomic region.
- the culture of DT40- # 7 was performed in G418-DT40 medium as in Example 14. About 10 7 DT40- # 7 cells were washed once with RPMI1640 medium without FBS, suspended in 0.5 ml of RPMI1640 medium without FBS, and linearized with the restriction enzyme Sfil (Toyobo). 1) Add 25-30 g of pTELPuro5.3 (F) or pTELPuro5.3 (R), transfer to a cuvette (BioRad) for election port po- ration, and allow to stand at room temperature for 10 minutes. The cuvette was set on a Gene Pulser (Bio-Rad), and voltage was applied at 550 V and 25 ° F.
- F pTELPuro5.3
- R pTELPuro5.3
- DT40 medium containing puromycin (0.3 i / ml) (hereinafter abbreviated as Puro-DT40 medium), dispensed into five 96-well culture plates, and selectively cultured for about two weeks.
- Puro-DT40 medium DT40 medium containing puromycin (0.3 i / ml)
- Genomic DNA was extracted from the puromycin-resistant clones using a Puregene DNA Isolation Kit (Gentra System). This genomic DNA is treated with restriction enzymes Sphl (Takara Shuzo), Hpal (Takara Shuzo) and Xhol (Toyobo), electrophoresed in 0.8% agarose gel, and GeneScreen Plus TM hybridization transfer.
- Membrane (NEN TM Life Science Products, Inc.) was subjected to alkaline blotting. Using the PS11 probe obtained by amplifying the gene sequence in AF006752 by PCR on this filter, Southern hybridization was performed to identify homologous recombinants (FIG. 11). PS11 Preparation of probe PCR was performed as ⁇ the DT40- # 7 genomic DNA using Buraima one below, to produce a 32 P-labeled DNA probe by random ply Mi ring the PCR product as ⁇ (Amersham, According to the attached protocol).
- PCR For PCR, use GeneAmp2400 manufactured by Perkin-Elmer as a thermal cycler, EX Taq (Takara Shuzo) for Taq polymerase, and use the buffer and dNTP (dATP, dCTP, dGTP, dTTP) according to the recommended conditions.
- the temperature and cycle conditions were as follows: heat denaturation at 93 ° C for 5 minutes, followed by 35 cycles of 93 ° C for 1 minute, 54 ° C for 1 minute, and 72 ° C for 1 minute. It was predicted by Southern hybridization that a band of about 14.9 kb was detected for the heterologous recombinant and about 9.6 kb for the homologous recombinant (FIG. 11).
- the temperature and cycle conditions were as follows: heat denaturation at 95 ° C for 2 minutes, followed by 35 cycles of 94 ° C for 45 seconds, 55-60 ° C for 45 seconds, and 72 ° C for 1 minute.
- Table 4 shows the results. ⁇ indicates positive and X indicates negative.
- telomere end of the human chromosome 7 fragment was detected at one end of the newly formed telomere near 7q22. This indicated that the AF006752 locus was at the telomere end of the human chromosome 7 fragment.
- PCR confirmed the deletion of a marker on the telomere side of the AF006752 locus, which is the telomere insertion site, and chromosome fragmentation in all 50 cell division images observed by FISH. was visually confirmed to be a truncated form, and this DF141 clone was subjected to subsequent experiments.
- Example 20 Site-specific insertion of loxPHyg cassette in chicken DT40 cells on human chromosome 7 Fragment of human chromosome 7 fragment cut in the AF006752 genomic region obtained in Example 19 above
- the cuvette was set in a Gene Pulser (BioRad) and a voltage was applied at 550 V and 25 F. After standing at room temperature for 10 minutes, the cells were placed in DT40 medium for 24 hours. After 24 hours, the medium is replaced with DT40 medium containing hygromycin B (lmg / ml) (hereinafter abbreviated as Hyg-DT40 medium), dispensed into five 96-well culture plates, and selective culture is performed for about 2 weeks.
- Hyg-DT40 medium DT40 medium containing hygromycin B (lmg / ml) (hereinafter abbreviated as Hyg-DT40 medium), dispensed into five 96-well culture plates, and selective culture is performed for about 2 weeks.
- Genomic DNA was extracted from the hygromycin B resistant clones using a Puregene DNA Isolation Kit (Gentra System). At C0L1A2 site The homologous recombinants were identified by PCR using the following primer
- PCR For PCR, use GeneAmp2400 manufactured by Perkin-Elmer as a thermal cycler, use LA Taq (Takara Shuzo) for Taq polymerase, and use buffers and dNTPs (dATP, dCTP, dGTP, dTTP) according to the recommended conditions. .
- the temperature and cycle conditions were as follows: heat denaturation at 85 ° C for 3 minutes and 94 ° C for 1 minute, and then 30 cycles of 98 ° C for 10 seconds and 65 ° C for 15 minutes.
- amplification is performed with the loxPHyg cassette introduced in a site-specific manner (Fig. 9). Was detected.
- HYGR01 5, -ATGGTTTCTACAAAGATCGTTATGTTTATC-3 : (SEQ ID NO : 74)
- HYGR01 5'-ATGGTTTCTACAAAGATCGTTATGTTTATC-3 : (SEQ ID NO : 76)
- GeneAmp2400 manufactured by Perkin-Elmer as a thermal cycler
- LA Taq Taq
- dNTP dATP, dCTP, dGTP, dTTP
- the temperature and cycle conditions were as follows: heat denaturation at 85 ° C for 3 minutes and 94 ° C for 1 minute, and then 30 cycles of 98 ° C for 10 seconds and 65 ° C for 15 minutes.
- Example 2 1 Preparation of Targeting Vector—pRNR21oxPbsr
- a targeting vector, pMR21oxPbsr, for inserting the ⁇ sequence into the RNR2 locus on human chromosome 4 was prepared as follows. First, the genomic region of the human RNR2 locus was amplified by PCR using the following primers.
- PCR For PCR, use GeneAmp9600 manufactured by Perkin-Elmer as a thermal cycler and LA Taq (Takara Shuzo) for Taq polymerase, and use the buffer and dNTP (dATP, dCTP, dGTP, dTTP) according to the recommended conditions. Using. The temperature and cycle conditions were as follows: heat denaturation at 94 ° C for 1 minute, and 35 cycles of 98 ° C for 10 seconds and 68 ° C for 15 minutes. After the PCR product was treated with proteinase K (Gibco), it was subjected to gel filtration with CHROMA SPIN-TE400 (Clontech).
- Plasmid PRNR2 was prepared by cloning the above PCR fragment of the RNR2 gene into the EcoRI site of plasmid [pBS (K) Sr].
- Kpnl linker (Takara Shuzo) was inserted into the Sfil site of cassette vector ploxPbsr, a DNA fragment containing the ⁇ sequence was cut out with the restriction enzyme Kpnl (Boehringer), and cloned into the Kpnl site of plasmid pR2.
- Example 22 Site-specific human loxPbsr cassette on human chromosome 14 in chicken DT40 cells Human chick DT40 cells carrying SC14 fragment SC20 (Toshitori University School of Medicine Oshimura (Provided by the professor), transfection of the targeting vector pR21ox Pbsr prepared in Example 21 above, and insertion of a loxPbsr cassette into the RNR2 locus was attempted.
- PCR For PCR, use GeneAnip9600 manufactured by Perkin-Elmer as thermal cycler, use LA Taq (Takara Shuzo) for Taq polymerase, and use the attached buffer and dNTP (dATP, dCTP, dGTP, dTTP) according to the recommended conditions. Using. The temperature and cycle conditions were as follows: heat denaturation at 94 ° C for 1 minute, and 35 cycles of 98 ° C for 10 seconds and 65 ° C for 5 minutes. As a result, a PCR product of about 2.5 kb was amplified as expected in 8 out of 60 clones. As a result, a homologous recombinant was obtained (referred to as R clone).
- Example 23 Construction of Human Artificial Chromosome # 7-HAC Having 3 Human CYP3A Genetic Mosquito Clusters
- the human chromosome 7 consisting of C0L 1A2-CYP3A-AF006752tel was translocated to the RNR2 locus on human chromosome 14 fragment SC20 to obtain a human artificial chromosome having the human CYP3A gene cluster.
- both the human chromosome 7 fragment and the human chromosome 14 fragment SC20 fragment were fused by cell fusion of the homologous recombinant TF and TR clones obtained in Example 20 above with the homologous recombinant R clone.
- a DT40 hybrid to be retained was prepared.
- the R clone was cultured on bsr-DT40 medium, and the TF and TR clones were cultured on Hyg-DT40 medium. 1 to 2 ⁇ 10 7 TF clones and R clones were mixed, centrifuged, and washed twice with serum-free RPMI 1640 medium. After the residual medium was completely removed, 0.5 ml of 50% PEG 1500 (Roche Diagnostics), which had been kept at 37 ° C in advance, was gently added, and mixed vigorously by pipetting for about 2 minutes.
- the medium was replaced with DT40 medium containing blasticidin S (10 / z g / ml) and hygromycin B (1 mg / ml), dispensed into five 24-well culture plates, and cultured for 3 to 4 weeks.
- the TR clone and the R clone were also fused. Genomic DNA was extracted from the hybrid obtained from the cell fusion of the TF clone and the R clone and the hybrid obtained from the cell fusion of the TR clone and the R clone, and PCR was performed using the following primers. It was confirmed that two of the human chromosomes 14 and 7 were retained.
- 3A4R7 5 '-GGCTGCATCAGCATCATCTA-3 5 ( SEQ ID NO: 82)
- VH3F 5'-AGTGAGATAAGCAGTGGATG-3 '(SEQ ID NO: 83)
- VH3R 5,-CTTGTGCTACTCCCATCACT-3, (SEQ ID NO: 84)
- PCR For PCR, use GeneAmp2400 manufactured by Perkin-Elmer as thermal cycler and Ex Taq (Takara Shuzo) for Taq polymerase, and use the attached buffer and dNTP (dATP, dCTP, dGTP, dTTP). Used according to recommended conditions. The temperature and cycle conditions were as follows: after heat denaturation at 94 ° C for 1 to 5 minutes, 40 cycles were performed at 98 ° C for 30 seconds, 54 to 58 ° C for 30 seconds to 1 minute, and 72 ° C for 30 seconds. This experiment confirmed that a PCR product was obtained with the above two sets of primers.
- dNTP dATP, dCTP, dGTP, dTTP
- the Cre recombinase expression vector pBS185 (Gibco) was digested with the restriction enzyme EcoRI (Beilinger), and Bglll linker was inserted (pBS185Bg).
- plasmid # 1-132 which contains a histinol-resistant gene cassette (provided by Professor Shunichi Takeda, Faculty of Medicine, Kyoto University)
- BamHI Boehringer
- the Cre recombinant enzyme stable expression vector pBS185hisD linearized with the restriction enzyme Kpnl is transfected into RTF and RTR hybrid clones, and histidine (lmg) / ml) for about 2 weeks. Then, dispense histidine-resistant cells into a 6-well culture plate and extract genomic DNA. Perform PCR using the extracted genomic DNA as a template and the following primers to confirm recombination between chromosomes.
- GFP Antisense
- PCR For PCR, use GeneAmp2400 manufactured by Perkin-Elmer as thermal cycler, Ex Taq (Takara Shuzo) for Taq polymerase, and use the attached buffer and dNTP (dATP, dCTP, dGTP, dTTP) as recommended conditions. Use according to.
- the temperature and cycle conditions are as follows: after heat denaturation at 94 ° C for 1 minute, 35 cycles of 98 ° C for 10 seconds, 61 ° C for 30 seconds, and 72 ° C for 1 minute. As a result, a PCR product of about 600 bp as shown in FIG. 15 is obtained.
- nested PCR using the product obtained by this PCR as a template was performed. Detect recombination.
- the nested PCR uses the PCR product 1 ⁇ 1 amplified by the primers of PGK (SEQ ID NO: 85) and GFP (SEQ ID NO: 86) as a template, and as the primer for nested PCR, the primer for identifying the mouse Cyp3a cluster-deleted cell strain. Perform PCR using the same primers (SEQ ID NOs: 60 and 61).
- PCR For PCR, use GeneAmp2400 manufactured by Perkin-Elmer as thermal cycler, Ex Taq (Takara Shuzo) for Taq polymerase, and use buffers and dNTPs (dATP, dCTP, dGTP, dTTP) according to the recommended conditions. .
- the temperature and cycle conditions are as follows: after heat denaturation at 94 ° C for 1 minute, 35 cycles of 98 ° C for 10 seconds, 59 ° C for 30 seconds and 72 ° C for 30 seconds. This confirms that translocated cells are included in the resistant cell population from which a PCR of about 200 bp was obtained.
- the GFP gene is reconstructed and expressed, so that the translocated cells can be detected by FACS.
- the GFP-positive cells are cloned by repeating the sorting of the cell fractions that appear to be GFP-positive several times.
- a human 14qter-specific probe (detecting the long arm telomere region of chromosome 14 of human, FITC labeling) and a pGKPuro probe (long arm telomere region of human chromosome 7 fragment) were used for GFP-positive clones.
- FISH using detection and rhodamine labeling to confirm that the FITC signal and the rhodamine signal are detected in both terminal telomere regions on the same chromosome.
- perform FISH with a human chromosome 14-specific probe and a human chromosome 7-specific probe and confirm that signals derived from both probes are observed on the same chromosome.
- the GFP positive DT40 culturing hybrid with 0.99 mm Petri dish 8 Like it it diameter, 20% FBS as they become Konfuruento, 13 ⁇ 4 two Wa avian serum, 10- 4 M 2-mercaptoethanol, 0. 05 mg / Replace with RPMI 1640 medium supplemented with ml corsemide and incubate for another 36 hours to form microcells. Suspend cells in 24 ml serum RPMI 1640 medium And, dispensed 2 ml each minute centrifuge 25 cm 3 flasks 1 2 were previously coated with 100 mg / ml of poly L- lysine (co-learning), incubated for 1 hour at 37 ° C, cells flasks Attach to the bottom.
- cytochalasin B (10 mg / ml, Sigma) solution that has been kept at 37 ° C in advance, and centrifuge at 8000 rpm for 1 hour at 34 ° C. Suspend the microcells in serum-free DMEM medium and purify with an 8 ⁇ m filter and a 5 ⁇ m filter. After purification, centrifuge at 1700 rpm for 10 minutes and suspend in 5 ml of serum-free DMEM medium. On the other hand, about 10 7 CH0 cells peeled by trypsin treatment, washed twice with serum-free DMEM medium, suspended in serum-free DMEM medium 5 ml.
- the CH7 cells holding # 7-HAC obtained in Example 24 above are introduced into mouse ES cells.
- the precipitate is sufficiently loosened by tapping, and a 1: 1.4 PEG solution [5 g PEG 1000 (Wako Pure Chemicals), 1 ml DMS0 (Sigma) dissolved in 6 ml of DMEM] Add 0.5 ml and stir well for about 1 minute 30 seconds. Then, slowly add 10 ml of DMEM, centrifuge at 1250 rpm for 10 minutes, suspend the cells in 30 ml of ES medium, and divide the cells into three 100 mm diameter dish (coining) seeded with feeder cells in advance. Inject and incubate. After 24 hours, replace with a medium containing 300 mg / ml G418 and selectively culture for about 1 week.
- Example 26 Preparation of Chimeric Mice Carrying 6 Human Artificial Chromosome # 7-HAC An ES cell clone selected in Example 25 above was cloned into ICR or MCH (CLEA Japan) female and male mice at the 8-cell stage. Inject 10-12 cells per embryo.
- a chimeric non-human mammal into which a human P450 gene group has been introduced at the chromosome level has a specific expression of the P450 gene in the liver and small intestine, which are the main organs expressing human P450 genes. Tissue specificity for drug metabolism can be reproduced in non-human mammal individuals.
- non-human mammal of the present invention has a human P450 gene group introduced at a chromosome level, it is considered that the gene sequence necessary for the regulation of expression is also included in this. You. Therefore, chimeric non-human mammals induce human P450 expression.
- the drug can induce the expression of human P450 in non-human mammal individuals.
- knockout non-human mammals in which the endogenous P450 gene of the non-human mammal serving as the counterpart is disrupted can not only provide important knowledge about the function of the human P450 gene, but also It is considered that offspring produced by mating with a non-human mammal or its progeny into which the P450 gene group has been introduced are completely humanized with respect to a specific P450 molecular species. Therefore, it is thought that not only the tissue specificity of expression, the rate of drug induction or expression, but also the metabolic function can be provided for human P450-introduced non-human mammals completely humanized with respect to specific P450 molecular species .
- human P450 protein can be supplied stably. Furthermore, it can be used as research material in culture systems for drug metabolism in humans.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU64760/00A AU6476000A (en) | 1999-08-13 | 2000-08-11 | Mouse having human cytochrome p450 transferred therein |
EP00951968A EP1206906A4 (en) | 1999-08-13 | 2000-08-11 | MOUSE CONTAINING A HUMAN P450 CYTOCHROME |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/229094 | 1999-08-13 | ||
JP22909499 | 1999-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001011951A1 true WO2001011951A1 (en) | 2001-02-22 |
Family
ID=16886670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/005424 WO2001011951A1 (en) | 1999-08-13 | 2000-08-11 | Mouse having human cytochrome p450 transferred therein |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1206906A4 (ja) |
AU (1) | AU6476000A (ja) |
WO (1) | WO2001011951A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1390500A1 (en) * | 2001-04-18 | 2004-02-25 | Gene Stream Pty Ltd. | Transgenic non-human animals for pharmacological and toxicological studies |
WO2004022738A1 (en) * | 2002-09-09 | 2004-03-18 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
US7531712B2 (en) | 2000-11-01 | 2009-05-12 | The University Of Syndey | P450 gene regulation |
WO2009063722A1 (ja) | 2007-11-14 | 2009-05-22 | National University Corporation Tottori University | ヒトチトクロームp450遺伝子(クラスター)を含む哺乳動物人工染色体ベクター及びそれを保持する非ヒト哺乳動物 |
US7638614B2 (en) | 1998-05-21 | 2009-12-29 | The University Of Sydney | Xenobiotic related induction of gene expression |
JP2010538632A (ja) * | 2007-09-14 | 2010-12-16 | アイティーアイ・スコットランド・リミテッド | 二段階のクラスター欠失及びヒト化 |
JP2011500048A (ja) * | 2007-10-19 | 2011-01-06 | アイティーアイ・スコットランド・リミテッド | P450遺伝子クラスターに関するノックアウトマウス |
WO2011083870A1 (ja) | 2010-01-06 | 2011-07-14 | 国立大学法人鳥取大学 | マウス人工染色体ベクター |
WO2013054949A1 (ja) * | 2011-10-13 | 2013-04-18 | 株式会社フェニックスバイオ | ヒト肝細胞を担持するキメラ非ヒト動物 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
WO2002088305A2 (en) | 2001-04-12 | 2002-11-07 | Xenogen Corporation | Isolation and identification of mouse and human transcription control elements associated with cytochrome expression |
CN100448992C (zh) | 2001-05-11 | 2009-01-07 | 麒麟医药株式会社 | 含人抗体λ轻链基因的人类人工染色体 |
GB0216203D0 (en) * | 2002-07-12 | 2002-08-21 | Imp Cancer Res Tech | Mondulation of cytochrome P450 reductase activity |
US7700822B2 (en) | 2002-07-12 | 2010-04-20 | Cancer Research Technology Limited | Modulation of cytochrome P450 reductase activity |
GB0402318D0 (en) * | 2004-02-03 | 2004-03-10 | Imp Cancer Res Tech | Transgenic animals for assessing drug metabolism and toxicity in man |
US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
US20060241073A1 (en) * | 2005-04-20 | 2006-10-26 | Wanders Ronaldus J A | Means and methods for counteracting fatty acid accumulation |
GB2457808A (en) * | 2008-02-27 | 2009-09-02 | Cancer Rec Tech Ltd | Non-human transgenic animals with cytochrome b5 deletion |
US20110189049A1 (en) | 2008-05-09 | 2011-08-04 | Martin Beaulieu | Method for treating odors |
PL2419196T3 (pl) | 2009-04-14 | 2018-01-31 | Uniboard Canada Inc | Sposób zmniejszania zawartości rozpuszczalnych w wodzie lotnych związków organicznych w gazie |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0773288A2 (en) * | 1995-08-29 | 1997-05-14 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
WO1998037757A1 (fr) * | 1997-02-28 | 1998-09-03 | Kirin Beer Kabushiki Kaisha | Cellules multipotentes comprenant des genes intrinseques dissocies |
-
2000
- 2000-08-11 EP EP00951968A patent/EP1206906A4/en not_active Withdrawn
- 2000-08-11 WO PCT/JP2000/005424 patent/WO2001011951A1/ja not_active Application Discontinuation
- 2000-08-11 AU AU64760/00A patent/AU6476000A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0773288A2 (en) * | 1995-08-29 | 1997-05-14 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
WO1998037757A1 (fr) * | 1997-02-28 | 1998-09-03 | Kirin Beer Kabushiki Kaisha | Cellules multipotentes comprenant des genes intrinseques dissocies |
Non-Patent Citations (10)
Title |
---|
GU H. ET AL, SCIENCE, vol. 265, 1994, pages 103 - 106, XP002933726 * |
JACOBOVITS A. ET AL, NATURE, vol. 362, 1993, pages 255 - 258, XP002933722 * |
LI H. ET AL, ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 329, no. 2, 1996, pages 235 - 240, XP002933727 * |
LI Z.W. ET AL, PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 6158 - 6162, XP002933725 * |
NELSON D.R. ET AL, PHARMACOGENETICS, vol. 6, 1996, pages 1 - 42, XP002933720 * |
RAMSDEN R. ET AL, J. BIOL. CHEM., vol. 268, no. 29, 1993, pages 21722 - 21726, XP002933299 * |
See also references of EP1206906A4 * |
SHIINA T. ET AL, GENOMICS, vol. 47, 1998, pages 372 - 382, XP002933723 * |
TETSUYA KAMATAKI ET AL, YAKUBUTSU DOUTAI, vol. 13, no. 3, 1998, pages 280 - 286, XP002933300 * |
TOMIZUKA K. ET AL, NATURE GENETICS, vol. 16, 1997, pages 133 - 143, XP002933721 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9029336B2 (en) | 1998-05-20 | 2015-05-12 | The University Of Sydney | Xenobiotic related induction of gene expression |
US7638614B2 (en) | 1998-05-21 | 2009-12-29 | The University Of Sydney | Xenobiotic related induction of gene expression |
US8629318B2 (en) | 2000-11-01 | 2014-01-14 | University Of Sydney | Transgenic animals for analyzing CYP3A4 cytochrome P450 gene regulation |
US7531712B2 (en) | 2000-11-01 | 2009-05-12 | The University Of Syndey | P450 gene regulation |
US8088968B2 (en) | 2000-11-01 | 2012-01-03 | The University Of Sydney | Transgenic animals for analyzing CYP3A4 cytochrome P450 gene regulation |
EP2316959A3 (en) * | 2001-04-18 | 2011-08-24 | Gene Stream Pty Ltd. | Transgenic non-human animals for pharmacological and toxicological studies |
US8524975B2 (en) | 2001-04-18 | 2013-09-03 | Gene Stream Pty Limited | Method of predicting a behavior of one or more drugs |
US7781643B2 (en) | 2001-04-18 | 2010-08-24 | Gene Stream Pty Limited | Transgenic non-human animals for pharmacological and toxicological studies |
US9497944B2 (en) | 2001-04-18 | 2016-11-22 | Gene Stream Pty Limited | Mouse for predicting a behavior of drugs in humans |
EP1390500A4 (en) * | 2001-04-18 | 2007-02-28 | Gene Stream Pty Ltd | TRANSGENIC ANIMALS FOR PHARMACOLOGICAL AND TOXICOLOGICAL STUDIES |
US7544854B2 (en) | 2001-04-18 | 2009-06-09 | Gene Stream Pty Limited | Transgenic non-human animals for pharmacological and toxicological studies |
EP2336338A3 (en) * | 2001-04-18 | 2011-08-03 | Gene Stream Pty Ltd. | Transgenic non-human animals for pharmacological and toxicological studies |
EP1390500A1 (en) * | 2001-04-18 | 2004-02-25 | Gene Stream Pty Ltd. | Transgenic non-human animals for pharmacological and toxicological studies |
US8148599B2 (en) | 2001-04-18 | 2012-04-03 | Gene Stream Pty Limited | Transgenic non-human animals for pharmacological and toxicological studies |
WO2004022738A1 (en) * | 2002-09-09 | 2004-03-18 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
JP2010538632A (ja) * | 2007-09-14 | 2010-12-16 | アイティーアイ・スコットランド・リミテッド | 二段階のクラスター欠失及びヒト化 |
JP2011500048A (ja) * | 2007-10-19 | 2011-01-06 | アイティーアイ・スコットランド・リミテッド | P450遺伝子クラスターに関するノックアウトマウス |
WO2009063722A1 (ja) | 2007-11-14 | 2009-05-22 | National University Corporation Tottori University | ヒトチトクロームp450遺伝子(クラスター)を含む哺乳動物人工染色体ベクター及びそれを保持する非ヒト哺乳動物 |
JP4997544B2 (ja) * | 2007-11-14 | 2012-08-08 | 国立大学法人鳥取大学 | ヒトチトクロームp450遺伝子(クラスター)を含む哺乳動物人工染色体ベクター及びそれを保持する非ヒト哺乳動物 |
US8951789B2 (en) | 2007-11-14 | 2015-02-10 | National University Corporation Tottori University | Mammalian artificial chromosome vector comprising human cytochrome P450 gene (cluster) and non-human mammalian animal retaining the same |
WO2011083870A1 (ja) | 2010-01-06 | 2011-07-14 | 国立大学法人鳥取大学 | マウス人工染色体ベクター |
WO2013054949A1 (ja) * | 2011-10-13 | 2013-04-18 | 株式会社フェニックスバイオ | ヒト肝細胞を担持するキメラ非ヒト動物 |
JP2013085485A (ja) * | 2011-10-13 | 2013-05-13 | Phoenix Bio:Kk | ヒト肝細胞を担持するキメラ非ヒト動物 |
US9420769B2 (en) | 2011-10-13 | 2016-08-23 | Phoenixbio Co., Ltd. | Chimeric non-human animal carrying human hepatocyte |
Also Published As
Publication number | Publication date |
---|---|
EP1206906A1 (en) | 2002-05-22 |
EP1206906A4 (en) | 2004-12-29 |
AU6476000A (en) | 2001-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001011951A1 (en) | Mouse having human cytochrome p450 transferred therein | |
US6025155A (en) | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes | |
JP4997544B2 (ja) | ヒトチトクロームp450遺伝子(クラスター)を含む哺乳動物人工染色体ベクター及びそれを保持する非ヒト哺乳動物 | |
US6077697A (en) | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes | |
EP0613495B1 (en) | Transgenic non-human animals lacking prion proteins | |
WO1997007671A1 (fr) | Animal chimerique et procede de constitution | |
WO2006044492A2 (en) | Methods for generating rat embryo-derived cell lines and genetic modification of rat genome | |
WO1996027395A1 (en) | Gene-targeted non-human mammals deficient in the sod-1 gene | |
WO2000072670A1 (fr) | Animaux rompant le gene lkb1 | |
JP2006094849A (ja) | 相同組換え効率が向上した分化多能性細胞及びその利用 | |
JP3741447B2 (ja) | エンドセリン−1遺伝子の機能が欠損したマウス | |
JP2000503538A (ja) | 細胞周期を仲介する組成物および方法 | |
JP2005504552A (ja) | ターゲティングベクターの調製方法およびその使用 | |
US6284944B1 (en) | Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring | |
AU712016B2 (en) | Ikaros transgenic cells and animals | |
JP2001136866A (ja) | 好中球走化性因子lect2遺伝子の機能が欠損したマウス | |
JP4590629B2 (ja) | Psf1遺伝子欠損動物およびその利用方法 | |
JPH07246040A (ja) | ニューロトロフィン−3遺伝子が不活性化された胚幹細胞および該遺伝子発現不全動物 | |
CA2242382C (en) | Compositions and methods for mediating cell cycle progression | |
WO2004032615A1 (ja) | ブラディオン遺伝子発現抑制キメラマウス | |
EP1034257A2 (en) | Yac vectors | |
Yin | Expression and developmental requirement for transcription factor Sp2 | |
WO2002059140A2 (en) | Ikaros rgulatory elements and uses thereof | |
JPH10295216A (ja) | ボンベシン様ペプチド受容体遺伝子機能欠損非ヒト動物 | |
JP2003116407A (ja) | ラディキシンノックアウト動物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000951968 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000951968 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10049373 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000951968 Country of ref document: EP |